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Abstract
Over 50% of all drug candidates entering clinical trials are abandoned due to insufficient efficacy
or unexpected safety issues despite extensive pre-clinical testing. Liver metabolites that cause toxicity or
other side effects cannot always be predicted in animals, in part because of human-specific drug
metabolism. Furthermore, while the clinical need for cancer drugs is increasing, anti-tumor activity in
animals often leads to a disappointing lack of efficacy in real patients. In vitro models that can better
predict human responses to drugs would mitigate the overall costs of development and help bring new
therapies to market. In order to improve the predictive power of in vitro tissue models, various features of
the microenvironment that modulate cell behavior have been investigated, such as cell-cell interactions,
cell-matrix interactions, soluble signals, 3-dimensional (3D) architecture, and mechanical stiffness.
Synthetic hydrogels offer a versatile platform within which these cues can be precisely perturbed in a 3D
context; however, the throughput of these methods is quite limited. In this thesis, we explore the potential
of high-throughput manufacturing and monitoring of populations of miniaturized 3D tissues, termed
'microtissues,' for modeling healthy and diseased tissues in both static and perfused systems.
First, we developed a flow-based platform to test tumor proliferation in defined
microenvironmental settings with large numbers of replicates (n > 1000). A microfluidic droplet generator
was designed to encapsulate tumor cells with stromal cells and extracellular matrix in 100 pm-diameter
poly(ethylene glycol) (PEG) microtissues (6000 microtissues/min). Upon screening a small panel of soluble
stimuli, TGF-p and the TGF-pR1/2 inhibitor LY2157299 were found to have opposing effects on the
proliferation of lung adenocarcinoma cells in microtissues vs. in 2-dimensional culture, affirming a
potential role for 3D models in the investigation of cancer therapies.
Next, we extend these techniques to the analysis of drug-induced liver injury. Phenotypic
maintenance of primary hepatocytes was achieved by controlled pre-aggregation (-50 tm units) with
J2-3T3 fibroblasts to establish cell-cell contacts prior to encapsulation into microtissues. Retention of both
constitutive and inducible Phase I drug metabolism activity allowed detection of prototypical
hepatotoxins through generation of toxic metabolites and emergence of drug-drug interactions, thereby
demonstrating the suitability of hepatic microtissues for 3D, high-throughput toxicity screening.
Finally, we describe efforts to bridge the gap between multi-organ models and human drug
metabolism. Modular human hepatocyte microtissues were entrapped by semi-circular microsieves in a
microfluidic perfusion chamber for over 3 weeks. In contrast to immortalized hepatic cell lines, primary
hepatocytes stabilized in microtissues exhibited human-specific induction profiles, reflected donor
hetereogeneity in CYP2D6 and CYP2C19 enzyme activity levels, and performed xenobiotic detoxification
on circulating drugs, establishing the ability to incorporate hepatic functions in 'human-on-a-chip' devices.
Collectively, these three applications of cell-laden microtissues demonstrate their versatility and
potential impact in both drug development and fundamental studies of the cellular microenvironment.
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and Technology & Electrical Engineering and Computer Science
Thesis Supervisor: Robert S. Langer Title: David H. Koch Institute Professor of Chemical Engineering
3
Acknowledgements
First and foremost, I want to express my deepest thanks to my advisor, Sangeeta Bhatia, who has
been a steady beacon of guidance and scientific vitality. Throughout this journey, she gave me room to
explore intellectually and fully supported my independence, but had this uncanny ability to step in and
ask "How's it going?" exactly when I needed it. Sangeeta has also carefully created a lab environment
that is warm and collaborative, for which I am very grateful. Thank you for being a wonderful role model
and teaching me not just how to do science, but also how to approach life's challenges (and celebrate
crazy ideas).
Next, I would like to thank my co-advisor Robert Langer, for offering his unequivocal support
and encouraging me to trust my instincts. I am also grateful to my thesis committee members Chris Love
and Darrell Irvine, who have been more than generous with their time and provided tremendous insights
and constructive feedback during our meetings.
In the lab, I owe gratitude to the many incredible scientists and individuals whom I've had the
honor of working with. In particular, to Neetu Singh and David Wood, who have respectively taught me
all things chemistry and microfluidics, thank you for being mentors and close confidants. I will miss our
conversations on all sorts of different topics. I thank Kelly Stevens for being the ultimate cheerleader and
for helping me navigate the academic landscape. I also thank Rob Schwartz for letting me take advantage
of his encyclopedic brain, and ensuring that the tissue culture room never went silent. To my friends in
the lab, thank you for being fun, unique, and always there for me. Kevin Lin, for everyday snax, chats,
and quiet companionship. Nathan Reticker-Flynn for never failing to notice new outfits, and for
establishing an excellent custom to greet unsuspecting lab members. Meghan Shan, for being my sole
source of peer estrogen with all the trappings, including shopping trips and girly talks. Kartik Trehan, for
sending me trendy YouTube links. Justin Lo, for your cheery imagination and artistic talent - purr.
Arnout Schepers, for offering unsolicited but gallingly effective suggestions. Gabe Kwong, for thoughtful
advice and for being inhumanly brilliant. David Malta and Vyas Ramanan, for wearing clever t-shirts,
Warren for taking up the baton, and the rest of the lab for being generally outstanding colleagues.
Thank you to my devoted undergraduates, Caroline Hsu, Joanne Huang, and Brian Alejandro,
for being excited, engaged, and in Brian's case very well dressed. This work could not have happened
without your contributions, and I hope it was a gainful learning experience for you. Thanks are also due
to our lab staff: to Steve Katz and Lia Ingaharro for making the lab run smoothly and keeping us in check.
To Heather Fleming, for being simultaneously an editor, advocate, therapist, and event planner. And last
but not least, to the gatekeeper Sue Kangiser, for taking care of everything else behind the scenes. I would
also like to acknowledge Elisa Vasile from the Microscopy Core, Alex Austin from Biopolymers &
Proteomics, and Dennis Ward and Kurt Broderick from the Microsystems Technology Laboratories.
This thesis is dedicated to my family, who have pushed me and buoyed me for so many years.
My mom, for her empathy and restless sense of adventure. My dad, for his insatiable curiosity and sage
strategies for feeding a grad student's appetite with minimal effort. And to my brother Michael, whom I
am so proud of, for always taking my side no matter what. I also thank the Seibert family for welcoming
me with open arms, and Lychee for encouraging high fives and staying up with me at night.
Finally, I would like to express my love and endless gratitude to Jeff, who has stood by me
through all the ups and downs of this experience, supporting me and inspiring me by the pursuit of his
own passions. In addition to his many known qualifications, Jeff is a master mixologist, ready to provide
liquid courage on a moment's notice, and an accomplished pirate, having commandeered the fastest ship
in the Caribbean. Thank you for encouraging me to follow my dreams, both big and small, even when
this meant craft supplies strewn everywhere from my latest whim. I can't wait to find out what the future
holds for us.
4
Table of Contents
A bstract ....................................................................................................................................................... 3
A cknow ledgem ents ................................................................................................................................... 4
Table of Contents ....................................................................................................................................... 5
List of Figures ............................................................................................................................................. 8
List of Tables...............................................................................................................................................9
Chapter 1: Introduction..........................................................................................................................10
1.1 The D rug D evelopm ent Pipeline ....................................................................................... 10
1.1.1 Pre-Clinical In Vivo A nim al M odels ......................................................................... 12
1.1.2 Cell-Based In Vitro M odels for D rug D evelopm ent................................................ 13
1.1.3 M icroenvironm ental Cues for Cell Behavior .......................................................... 15
1.2 Three-D im ensional Tissue Engineering............................................................................ 17
1.2.1 Scaffold M aterials in H epatic Tissue Engineering.................................................... 17
1.2.2 M iniaturized, 3D M icroenvironm ents ..................................................................... 19
1.2.3 Fabrication of Polym eric M icrotissues ..................................................................... 20
1.3 Scope of the D issertation..................................................................................................... 24
Chapter 2: Microtissue Fabrication and Templated Assembly ................................................. 26
2.1 Introduction .............................................................................................................................. 26
2.2 M aterials and M ethods............................................................................................................28
2.3 Results and D iscussion............................................................................................................34
2.3.1 H igh-throughput m icrotissue fabrication ................................................................ 34
2.3.2. Microtissue functionalization with surface-encoding DNA ................................. 36
2.3.3 Binding efficiency and specificity of DNA-templated assembly .......................... 40
2.3.4 DNA-templated assembly of multicellular tissue constructs ............................... 42
2.4 Conclusion ................................................................................................................................ 48
2.5 A cknow ledgem ents ................................................................................................................. 48
Chapter 3: Flow Analysis of Microenvironmental Effects on Tumor Proliferation........50
3.1 Introduction .............................................................................................................................. 50
5
3.2 M aterials and M ethods............................................................................................................53
3.3 Results and Discussion............................................................................................................56
3.3.1 Platform design ................................................................................................................ 56
3.3.2 Controlling tumor homotypic and heterotypic interactions................................. 60
3.3.3 Modulating cell proliferation with microenvironmental factors .......................... 64
3.3.4 Microenvironmental modulation of tumor drug response....................................68
3.4 Conclusion ................................................................................................................................ 72
3.5 A cknow ledgem ents ................................................................................................................. 74
Chapter 4: Hepatocyte Microtissues for Toxicity Screening and Drug-drug interactions........75
4.1 Introduction .............................................................................................................................. 75
4.2 M aterials and M ethods............................................................................................................77
4.3 Results........................................................................................................................................84
4.3.1 Control and uniform ity of hepatocyte patterning................................................... 84
4.3.2 Effect of hom otypic contacts on 3D album in secretion .......................................... 86
4.3.3 Effect of other supporting factors in 3D albumin secretion................................... 88
4.3.4 M icrofluidic production of hepatic m icrotissues...................................................... 90
4.3.5 Species-specific cytochrom e P450 enzym e activity ................................................. 94
4.3.6 A cetam inophen toxicity .............................................................................................. 94
4.3.7 Cytochrom e P450-m ediated drug-drug interactions .............................................. 96
4.4 Discussion ................................................................................................................................. 98
4.5 Conclusion .............................................................................................................................. 103
4.6 A cknow ledgem ents ............................................................................................................... 104
Chapter 5: Modular Construction of a Primary Human Liver-on-a-Chip .................................. 106
5.1 Introduction ............................................................................................................................ 106
5.2 M aterials and M ethods..........................................................................................................108
5.3 Results and Discussion..........................................................................................................117
5.3.1 Prim ary hepatocyte m icrotissue fabrication .............................................................. 117
5.3.2 Species- and donor-specific drug metabolizing enzyme activity............................119
5.3.3 Microtissue response to hepatotoxic drugs and drug interactions.........................123
5.3.4 Design and operation of m icrofluidic perfusion cham ber ....................................... 127
6
5.4 Conclusion .............................................................................................................................. 131
5.5 A cknow ledgem ents ............................................................................................................... 132
Chapter 6: Perspectives and Future D irection ................................................................................. 133
6.1 M icrofluidic Fabrication of 3D M icrotissues ...................................................................... 133
6.2 System atic Control of M icroenvironm ental Stim uli ......................................................... 134
6.3 H igh-Throughput 3D Phenotypic Screening ..................................................................... 135
6.4 Tow ards M odular Organ-on-a-Chip Devices .................................................................... 136
Bibliography .......................................................................................................................................... 139
7
List of Figures
1.1 Attrition of drug candidates during the development and testing process....................12
1.2 Schematic of microenvironmental inputs that modulate cellular behavior....................17
1.3 Batch and microfluidic processes to fabricate polymeric microparticles........................23
1.4 Controlling cellular microenvironment on several length scales.................................... 25
2.1 Schematic of microtissue encapsulation, functionalization, and DNA-templated
self assem b ly ............................................................................................................................... 28
2.2 Microencapsulation device.................................................................................................. 36
2.3 Microtissue functionalization with streptavidin and DNA......................................38
2.4 Optimization of acrylate-PEG-streptavidin conjugation................................................ 39
2.5 Capture efficiency and specificity of DNA-directed microtissue assembly...............41
2.6 Distribution of cell encapsulation numbers within microtissues............................44
2.7 Cell encapsulation and microtissue culture...........................................................45
2.8 Multi-photon images of fibroblast spreading within RGDS microtissues.....................47
2.9 Fibroblast-laden, RGD-decorated microtissues cultured in close contact and in the
presence of non-encapsulated fibroblasts....................................................................47
3.1 3D tumor microenvironment screening platform.............................................. 59
3.2 Correlation of number of (A) ZsGreen expressing 393T5 cells of (B) CellTracker FarRed
DDAO-stained J2-3T3 fibroblasts.................................................................................61
3.3 Control over homotypic and heterotypic microtissue composition........................63
3.4 Flow analysis and sorting of microtissues containing co-encapsulated tumor (393T5) and
strom al (J2-3T3) cells................................................................................................64
3.5 Modulation of tumor cell proliferation by cytokines and ECM.............................66
3.6 Epifluorescence microscopy of cell-free microtissues containing encapsulated
p rotein s............................................................................................................ . . 68
3.7 Comparison of 393T5 (A-B) and 394T4 (C-D) lung cancer cell response to drugs when
cultured in 3D microtissues (A,C) vs. in 2D monolayers (B,D).........................................70
4.1 Hepatocyte puck formation and detachment from patterned collagen microislands......85
4.2 Microisland seeding (A-C) and puck formation (D-F) by primary hepatocytes over large
a re a s ..................................................................................................................... 8 6
4.3 Hepatocyte pucks express liver proteins..........................................................87
4.4 2D culture of hepatocytes on either (A) micropatterned islands, or (B) unpatterned,
collagen-coated plastic.......................................................................................... 88
4.5 Hepatocyte pucks in 8.5mm-diameter bulk PEG hydrogels..................................89
4.6 Microfluidic encapsulation of hepatocyte pucks................................................92
4.7 Flow-focusing nozzle of microfluidic encapsulation device..................................93
4.8 Sequential seeding of hepatocytes and fibroblasts to form mixed pucks.....................93
4.9 Induction of cytochrome P450 activity in hepatocyte-fibroblast mixed-puck
m icrotissu es......................................................................................................... 94
8
4.10 Acetaminophen-induced microtissue hepatotoxicity.......................................96
4.11 Cytochrome P450 inducer interactions with acetaminophen toxicity...................97
5.1 Setup and operation of microtissue perfusion chamber.........................................114
5.2 Mixed hepatocyte-fibroblast spheroid formation in pyramidal microwells...............118
5.3 Albumin secretion by encapsulated primary human hepatocytes...........................119
5.4 Induction of cytochrome P450 activity in primary human hepatocyte microtissues....121
5.5 Comparison of cytochrome P450 activity between donor individuals......................123
5.6 Microtissue hepatotoxicity as measured by large particle flow cytometry.................124
5.7 Acetaminophen-induced hepatotoxicity in human hepatic microtissues...................125
5.8 Mechanism-based drug interactions with acetaminophen toxicity...........................126
5.9 M icrotissue trapping and perfusion device.........................................................128
5.10 Albumin detected in perfusate of Huh7.5 microtissue-loaded devices......................129
5.11 Characterization of hepatocyte functions in microtissue perfusion device................130
List of Tables
5.1 Donors of cryopreserved human hepatocytes......................................................109
9
Chapter 1: Introduction
1.1 The Drug Development Pipeline
New drug candidates undergo a gauntlet of tests before they reach the market, starting
with extensive pre-clinical characterization, in vitro assays, and in vivo animal studies. After this,
if a compound is selected for further development, it is assessed for the first time in humans
and undergoes three phases of clinical trials: Phase I, which tests for safety in a small
population of healthy participants, Phase II, which tests for effectiveness in a larger population
of diseased patients, and finally Phase III, which compares the drug to existing treatments in
hundreds to thousands of participants and continues to monitor for side effects. Despite the fact
that this process spans over a decade of time and costs on average more than $800 million
dollars per drug,1 many drugs are entered into clinical trials that will never be approved.
Because of this attrition rate, the cost of drug development is ultimately reliant on the
proportion of drugs that fail in the end - currently 8 out of 9 drugs entering clinical trials.2 The
ability to make swift, accurate decisions early in the process about which drugs are worth
pursuing would significantly reduce overall costs: the sooner a drug candidate that would have
failed can be eliminated from further development, the fewer resources are wasted.
Why are we so bad at identifying eventual losers? Accurately predicting the human
body's response to various drugs or drug combinations is difficult. Although there are several
factors that contribute to drug candidate failure, two major reasons for the attrition are 1) lack of
efficacy or 2) toxic side effects.3 The efficacy of a drug candidate is especially difficult to predict
10
for diseases with complex processes such as cancer. Phenotypic hetereogeneity of tumor cells
within a patient (or even within a given tumor),4-6 tumor cell interactions with stromal and
immune cells, 7 8 and acquired chemoresistance are only some of the issues hindering effective
cancer treatment. Indeed, oncology drugs have higher rates of Phase III failure than in any
other disease area, with only a 6% success rate from first-in-man tests to registration.2 Given the
desperate need for new antineoplastic agents, and assuming that drug candidates are not
entered into clinical trials without reasonable pre-clinical evidence of efficacy,6 this abysmal
success rate suggests that current pre-clinical disease models must be faulty.
Drug toxicity is inextricably linked to efficacy, as drugs are often given in ineffective
doses because safety concerns. The most common toxicity discovered in clinical trials is
unforeseen or idiosyncratic liver injury (hepatotoxicity),9"10 followed by kidney (nephrotoxicity)
and cardiac effects. The liver is often the first casualty because it is the primary organ
responsible for xenobiotic detoxification in the body. Unanticipated metabolism of a drug
candidate by the liver can affect its clearance time, alter the level of drug activity, or produce
metabolites that cause toxicity to the liver or other organs."-" Thus, for efficacy as well as
safety, pre-clinical models that enable better prediction of human liver metabolism and toxicity
would be indispensable in lead selection and early mitigation of potential problems.
11
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Figure 1.1. Attrition of drug candidates during the development and testing process. Adapted
from http://www.ncats.nih.gov, and http://www.manhattan-institute.org/html/fda 05.htm,
which based their findings on drugs first tested in humans between 1983-19941, The approval
rate of drugs entering clinical trials has continued to drop since then.2
1.1.1 Pre-Clinical In Vivo Animal Models
Currently, animals are widely used in pre-clinical studies as models to represent both
healthy and diseased states. For oncology testing, xenograft models are common in which a
tumor cell line is injected into an immune-compromised mouse.6 In vivo models like these offer
many advantages and allow examination of whole-organism effects such as bio-distribution,
pharmacokinetics and pharmacodynamics, organ-organ interactions, and off-target effects. At
the same time, animal models incur considerable costs, require lengthy experiments, can be
difficult to manipulate, and raise ethical issues. There is also substantial evidence that in many
cases animal models are not necessarily predictive of human behavior due to critical differences
in disease etiology, drug metabolism, and other species-specific characteristics. Xenograft
tumors for example are often in a location that does not correlate with the tumor origin (e.g.
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lung cancer cells injected subcutaneously into the flank of the mouse), and the tumor develops
over weeks instead of years in a human. More complex genetically engineered mouse models of
specific cancers are becoming available14-16 but are exorbitantly expensive. There have been
similarly heroic efforts to resolve the significant discrepancy between human and rodent drug
metabolism pathways, arising in part from different drug metabolizing cytochrome P450
enzymes or nuclear receptors that regulate levels of enzyme activity.17-19 Due to these
differences, animal models sometimes fail to distinguish drugs or drug combinations that may
be toxic only to the human liver via metabolism by a human-specific enzyme.11 20 Attempts to
"humanize" the mouse liver by injecting human hepatocytes are promising,21' 22 but remain
slow, finicky, and variable in the degree of humanization.
1.1.2 Cell-Based In Vitro Models for Drug Development
There is a clear need for pre-clinical models that can accurately and inexpensively assess
the response of humans to drug candidates. To do so, they must accurately represent important
facets of human tissue physiology before "first-in-human" trials are done. Experiments in vitro
have the potential to meet these requirements, as well as generally increase throughput, provide
early information for decision making, and reduce the need for animal studies. For example,
human liver microsomes and isolated enzymes have helped identify pathways involved in drug
metabolism.23 However, these assays lack the dynamic gene expression and intact cellular
machinery necessary for drug-interaction and toxicity testing, respectively. In vitro platforms
13
based on living cells are necessary to properly model the behavior of tissues with a multitude of
biochemical functions such as the liver.
For this particular organ, human liver slices and primary hepatocytes and have been
explored as cell-based models. Precision-cut liver slices retain structural tissue organization
and have been shown to accurately reflect the metabolic capabilities of the liver in vivo,23 but are
viable for only ~1 day and are not amenable to high-throughput screening. Primary hepatocytes
are thus ideal for studying ADME/TOX (absorption, distribution, metabolism, and
excretion/toxicity), 24-2 6 but are similarly difficult to stabilize in vitro and lose their drug
metabolism functions over the course of days.27, 28 Instead, hepatocellular carcinoma cell lines
are commonly used in place of primary hepatocytes, 29 but generally display abnormally low
levels of cytochrome P450 enzymes, 2 ,30 are less or non-responsive to known in vivo inducers of
enzyme activity,30 , 31 and are more resistant to hepatotoxins known to cause clinical drug-
induced liver injury. 32
The relevance of an in vitro model is critically dependent on the type and in vivo-like
phenotypic behavior of the cells used. Yet, proliferative cell lines cultured on 2D tissue culture
plastic remain the industry standard today despite their distorted representation of in vivo cells.
To improve the predictiveness of in vitro models, research efforts have turned towards learning
to better culture more "authentic" cells such as primary hepatocytes or induced pluripotent
stem cells that are more challenging to maintain,3 3 but could better reflect in vivo organ
behavior.
14
1.1.3 Microenvironmental Cues for Cell Behavior
Another factor that contributes to the limitations of conventional in vitro models is their
inability to capture critical features of the cellular microenvironment. The cellular
microenvironment, which includes extracellular matrix (ECM) interactions, cell-cell interactions,
tissue architecture, and soluble signals (e.g. growth factors and hormones), provides cues that
modulate cell behavior in both healthy and diseased tissues.344 1 In the case of liver models, the
in vivo structure of the liver is extraordinarily complex, 42 with hepatocytes arranged in cords
lined by ECM and sinusoidal endothelial cells. Other non-parenchymal cell types in the liver
include stellate cells and bile duct cells. When hepatocytes are isolated from this native
environment, they rapidly lose their hepatocyte-specific functions, 27 undergoing what is often
referred to as "de-differentiation".3 3 Efforts to stabilize hepatocyte phenotype in vitro have thus
focused optimizing culture conditions by recreating some of the appropriate
microenvironmental cues, such as medium supplements, 43-4 culture on or within added ECM, 43,
4s-ssand signals from non-parenchymal cells. 33,4,5 6 2 For instance, co-culture of hepatocytes with
fibroblasts, 9, 1, 63-65 endothelial, 62 or epithelial cells,66, 67 has been repeatedly shown to improve
long-term phenotypic stability. Within this body of work, it has become clear that hepatocytes
in 3-dimensional (3D) culture systems, for example in spheroids,3 , 6-o70 sandwich culture,4 9-5 2
porous scaffolds,71-74 or gel encapsulation,13-5 5, 71 show distinct phenotypic differences from
hepatocytes in 2D monolayer cultures with, in many cases, increased levels and maintenance of
albumin, urea, and cytochrome P450 metabolism. In general, 3D organization has been found to
affect cell viability, morphology, differentiation, proliferation, gene and protein expression, and
15
response to stimuli for a range of cell types in addition to hepatocytes, including stem cells7 6-8 0
and cancer cells. 81-85 Although the mechanisms have not been fully elucidated, these differences
between 3D and 2D are thought to be mediated through changes in cell-ECM and cell-cell
interactions. First, there is an increased surface area for both cell-ECM and cell-cell contacts in
3D, which more closely matches the in vivo situation where almost 100% of cell surface area is
exposed to other cells or matrix. This geometry modulates the types and amount of cell
interactions that occur; one example is the alteration of cell-cell contacts in 3D. 46 , 86-89
Furthermore, cell-ECM focal adhesions in 3D have been found to be composed of a different
distribution of integrins83 and other cytoskeletal components90 which interact with signaling
pathways within the cell, for example pathways downstream to growth factor binding.8 4 91, 92
The presence of matrix surrounding cells rather than under them can alter the presentation of
ligands 93 and the transport of nutrients or soluble signals.94 Finally, changes in mechanical
stimuli,9 -98 cell shape,90 99 and physical confinement 00 can also affect cell behavior. For all of
these reasons, it is possible that 3D culture is necessary to truly approach more predictive in
vitro models of cell behavior in response to therapies, especially as tissues in the body are 3-
dimensional. Tumor cells in cultured in 3D, for instance, have been shown to be significantly
more resistant to chemotherapeutics than in 2D.82,85-89,101 In this thesis, we aim to design three-
dimensional in vitro culture systems with sufficient microenvironmental complexity to maintain
in vivo human cell phenotypes, focusing on hepatocytes in particular. Such alternative pre-
clinical test platforms could form a crucial bridge between 2D experiments and developing
clinically viable drugs to treat human disease, and additionally enable manipulation of specific
environmental parameters to study underlying biological phenomena.
16
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Figure 1.2. Schematic of microenvironmental inputs that modulate cellular behavior.
Adapted from Alice Ann Chen.
1.2 Three-Dimensional Tissue Engineering
1.2.1 Scaffold Materials in Hepatic Tissue Engineering
As per the tissue engineering approach, hepatocytes have been cultured within various
natural and synthetic scaffolds. Some of the natural hydrogels used are agarose,102 alginate,103
collagen,54-55matrigel,104 or fibrin.105, 106 These hydrogel scaffolds not only provide structural
support to encapsulated cells while remaining permeable to oxygen and nutrients, but can also
interact with cellular process to modify cell behavior, for instance through integrin ligation,92
growth factor binding,0 7 or mechanical changes in response to secreted proteases.97 However,
the systematic examination of microenvironmental cues using such natural scaffolds is
17
challenged by lack of independent control over these biological interactions,94,108 -109 as well as by
batch to batch material variability. Synthetic polymer scaffolds can offer improved control over
scaffold features, mechanics, and the presentation of signals. 0 s, 110-112 In particular, poly (ethylene
glycol)-based (PEG) hydrogels have been investigated for the 3D culture of a wide range of cell
types including hepatocytes,n1 3-1 s osteoblasts, 6', 117 chondrocytes,118 , 119 fibroblasts,120 22
endothelial cells,1 23 pancreatic p-cells,124 and stem cells. 12 -12 There are various polymerization
techniques to form hydrogels from PEG, 121, 129-131 leading to different network structures, but a
shared feature is that resulting hydrogels are non- interactive with encapsulated cells because of
the neutral and hydrophilic PEG backbone. At the same time, advances in chemical
modifications have enabled methodical incorporation of further functionality, such as adhesive
peptides,114, 116, 122, 123 tethered growth 132-3 4 or inflammatory factors,13 enzyme mimetics136, or
degradable linkages. 1 17,121, 129, 130
While hydrogel encapsulation is an established approach for 3D cell culture, synthetic
tissue constructs are typically slow to fabricate and require large amounts of cells and reagents,
leading to experiments with generally low numbers of replicates (n-3-5). Moreover, the analysis
of cell behavior within the hydrogels can be technologically challenging.137 Current readouts can
be broken down into three categories: cell release, pooled biochemical assays, and imaging.
Cells can be released from confinement by enzymatic digestion of the scaffold,129 reversal of
ionic polymerization mechanisms (e.g. alginate13s), or simply brute hydrolysis. 133 Depending on
how gentle the method to degrade the gel is, released cellular components such as DNA can be
quantified, or intact cells can be analyzed by conventional 2D and suspension methods such as
flow cytometry. 139 This method is obviously destructive and can only be used for endpoint
18
studies. To probe the phenotype of cells still in a hydrogel, biochemical assays for properties
such as mitochondrial activity1 14, 116, 128 or protein secretion 14 14 0 can be performed as long as any
substrates or metabolites can permeate through the hydrogel network. However, these assays
integrate over the entire cell population in the hydrogel, and thus cannot distinguish subtleties
such as bimodal cell response outcomes. For imaging, the immobilization of cells in different
focal planes necessitates confocal microscopy for accurate quantification. Thus, even something
as simple as accurately measuring cell proliferation can require time-consuming image
acquisition and processing procedures.s, 125, 141 Sectioning of the hydrogels can be performed
similar to tissue histology,14 2 but is not compatible with all materials1 4 and is also destructive.
An ideal in vitro model would allow cell responses to treatment to be monitored over time.
1.2.2 Miniaturized, 3D Microenvironments
We propose that the miniaturization of cell-laden hydrogel scaffolds into small (<250 Pm
diameter) units of 3D engineered tissues, which we will call microtissues, could address some of
these limitations and bring unique advantages to the table. Compared to conventional 3D
hydrogels, which are often > 20 microliters in volume, each microtissue is on the order of 10
nanoliters, reducing the amount of cell and scaffold reagents needed, but most importantly
reducing the amount of experimental drug compounds needed to treat the microtissues, which
in early stages of development may only be produced in limited quantities. The length scale of
microtissues is also highly relevant to the in vivo architecture of the body: because the diffusion
distance of oxygen is approximately 150 jim in living tissues, cells in the body are located
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within at most 150 tm from the nearest blood supply.14 3-14 s Similarly, cells in microtissues would
remain less than this distance from the nearest medium supply, reducing concerns about
insufficient diffusion of oxygen and nutrients into the cells at the core of the hydrogel, even if
the local cell density of the microtissue is high and metabolically demanding. It has also been
found through studies manipulating cell-cell interaction distances that critical short-range cell
signaling occurs on the scale of hundreds of microns.146 Indeed, the organization of multiple cell
types in several organs is also seen to repeat on hundred-micron length scales (e.g. the liver ,
kidney, etc.42 ). Thus, microtissues are well poised to recapitulate tissue interactions at these
distances, and could additionally be suitable for bottom-up assembly of complex patterned
tissues.14 7, 148 Recently, Chen et al. demonstrated the suitability of microbead-labeled
microtissues for multiplexed in vivo experiments within an individual mouse, and illustrated
"fluid-phase" handling of microtissue suspensions. 149  For in vitro experiments, the
compatibility of microtissues with automated liquid handlers and microtiter plates is
indispensable toward achieving high throughput screening of cellular responses to drugs in
defined 3D microenvironments.
1.2.3 Fabrication of Polymeric Microtissues
Methods to fabricate microtissues fall under three categories, 1) physical molding, 2)
photolithography, and 3) emulsification. Large-scale production of uniform polymeric particles
has been achieved by a process called particle replication in non-wetting templates (PRINT).150
In this elegantly straightforward method, a patterned fluoropolymer mold with nano- to
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micron-scale indentations was used to make particles encapsulating proteins, DNA, and small
molecules.150 The PRINT process was integrated with roll-to-roll manufacturing techniques to
produce sufficient nanoparticles for clinical trials 151, but is incompatible with cell encapsulation.
Similar micromolding methods using elastomeric molds have been extended to template cell-
encapsulating hydrogel particles,5 2 but cytocompatible micromolding remains a batch process
with unproven production capacity. For photolithographically defined microtissues, a
hydrogel precursor is mixed with cells and a photoinitiator that triggers polymerization when
selected spatial regions are exposed to light, typically in the UV range 149, 153, 14. Dendukuri et
al. 155 and Panda et al.156 adapted hydrogel photolithography into a continuous microfluidic
process, but the technique can be challenging to execute and cell-encapsulation via "stop flow
lithography" has not become a widespread. Moreover, photolithography in general is wasteful:
prepolymer in un-exposed regions is discarded, which is a considerable inefficiency especially
when working with limited cell numbers or decorating the hydrogel with expensive bioactive
ligands.
Emulsification techniques can be applied in either macroscale or microfluidic settings. A
polymer precursor, usually in aqueous solution, is first broken up into droplets in a continuous
phase, usually oil. Yet macroscopic emulsions formed by agitation are generally polydisperse157 .
Instead, microfluidic devices containing a T-junction 158 -161 or flow-focusing junction1 , 162 can
generate monodisperse droplets, and have been used without the polymerization aspect for
applications like directed protein evolution163 , digital PCR15 8, 164 and single-organism (e.g.
yeast 165, C. elegans159, 166) droplet arrays. Alternatively, the droplets can then polymerized to
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form spherical or modified spherical shapes,160' 167, 168 which has been reported for both solid
polymer microspheres 168,169 and hydrogel particles. 170, 17 1 160,162
Continued advances in polymer microparticle fabrication, and specifically cell-laden
hydrogel microtissue fabrication as a small subset, will eventually lead to higher throughputs
and expand the library of shapes and materials that can be used. The larger problem is that of
the mammalian cell-laden microtissues thus far, encapsulated cells have been predominantly
limited to more robust fibroblast 152,156,172 or cancer, 149 , 154,172,173 or other immortalized cell lines. 1 7 1,
174 Moreover, cursory analysis of encapsulated cells entailed only staining for cell viability in the
short term.1 4 9, 152, 156, 171 Shear stresses, UV/free-radical damage, and chemical interactions with
scaffold components can cause more subtle but undesirable changes in cell behavior, such as
impaired growth rates or altered transcriptional profiles.175178 We reasoned that drug
development applications would require both manufacturing throughput and robust
maintenance of not just cell viability but also phenotype. Therefore, although the uniformity
and production rate of microfluidic droplet-based encapsulation is promising, it remains
unclear whether more sensitive but physiologically relevant cells such as hepatocytes can be
successfully encapsulated with maintenance of important drug metabolizing functions.
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Figure 1.3. Batch and microfluidic processes to fabricate polymeric microparticles. (A)
Molding of uniform particles in non-wetting perfluoropolyether (PFPE) molds. 15 0 (B)
Cytocompatible "micromolding" of cell-laden hydrogels in PDMS molds.17 9 (C) (D) Continuous
photolithography through a mask using "stop-flow lithography." 15 156 (E) Cell encapsulation
using batch aqueous-in-oil emulsion and photopolymerization.157 (F). Microfluidic T-junction
and flow-focused formation of aqueous-in-oil droplets. 174
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1.3 Scope of the Dissertation
Our overall goal is to create improved in vitro models of liver and tumor tissue for drug
development applications. Specifically, we hypothesize that 3D organization and encapsulation
of cancer cells or hepatocytes within miniaturized polymer hydrogels ("microtissues") that
provide appropriate cues will stabilize their tissue-specific phenotype ex vivo. In this thesis, we
construct and systemically manipulate microtissue-based microenvironmental parameters on
several length scales. Towards this end, we first aimed to develop a device that could
continuously encapsulate relevant cell types (i.e. primary human hepatocytes) into
customizable PEG microtissues. In Chapter 2, we establish methods to microfluidically generate
droplets of cells with prepolymer in fluorocarbon oil, and photopolymerize the droplets on-chip
to manufacture microtissues at a rate of -10 gels/hr. We then chemically modified the hydrogel
network to encode microtissues with specific biomolecular (DNA oligonucleotide) spatial
"addresses." These addresses template the binding of microtissues containing two cell types
into 2D and 3D heterostructures that enable secreted cell-cell interactions on the multiple-
microtissue length scale. Chapter 3 describes a high-throughput, high-powered (n > 1000) flow-
based assay to examine 3D tumor proliferation within microtissues in the presence of growth-
modulating cytokines or small molecule drug candidates, and demonstrates our ability to
control cellular microenvironment on a single-microtissue scale (homotypic/heterotypic cell
density, ECM proteins, soluble factors). Together, these chapters showcase unique advantages
of microtissue-based platforms in scalability, modularity, and versatility. In Chapter 4, we focus
on the long-term phenotypic maintenance of primary hepatocytes within microtissues (-weeks),
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which is achieved by pre-stabilizing hepatocytes through micropatterned cell-cell interactions,
and demonstrate the direct use of hepatocyte-laden microtissues for toxicity and drug
interaction studies. We extend these findings to primary human hepatocytes in Chapter 5, which
describes extensive characterization of microencapsulated human hepatocytes for organ-
specific, species-specific, and donor-specific drug metabolism functions. Finally, we load and
culture human hepatic microtissues in a perfused liver-on-a-chip device (Chapter 5), laying the
groundwork for future microtissue applications in multi-organ human-on-a-chip systems.
A B C
500 pm 100pm 40pm
Figure 1.4. Controlling cellular microenvironment on several length scales. (A) Multiple
microtissue scale (Chapter 2): templated distances for soluble-factor signaling between
microtissues containing different cell types. (B) Single microtissue scale (Chapter 3): selecting
microtissue populations with tightly gated parenchymal and stromal cell densities per
microtissue. (C) Within microtissues (Chapter 4): pre-stabilized cell-cell contacts for improved
viability and function.
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Chapter 2: Microtissue Fabrication and Templated Assembly
2.1 Introduction
The three-dimensional microscale architecture of living tissues provides vital
environmental cues, including extracellular matrix, soluble factors and cell-cell interactions.94 18 0
Paracrine and autocrine cell signaling are critical factors guiding tissue developmentis,1 1 2 and
maintenance,61 , 183 and dysregulation of these cues contributes to the pathogenesis of diseased
states such as cancer. 18 4-186 Understanding and emulating these cell-cell interactions has been
shown to be critical in engineering functional tissues in both 2D 14 6, 187-189 and 3D8 2, 114,1 90 systems.
In 3D culture, top-down approaches for organizing multiple cell types such as
dielectrophoresis,113, 191 photopatterning, 113, 192 and microfabrication1 93 provide high-precision
control over cell placement, but are challenging to scale-up for the assembly of mesoscale
tissues.
In contrast, bottom-up methods, wherein small tissue building blocks are assembled into
larger structures, have potential for creating multicellular constructs in a facile, scalable
fashion.194 -198 Living tissues are comprised of repeating units on the order of hundreds of
microns; therefore, synthetic microtissues comprised of cell-laden hydrogels in this size range149
represent appropriate fundamental building blocks of such bottom-up methods. Synthetic
microtissues of this size have been previously assembled in packed-bed reactors 94 199 or by
hydrophobic/hydrophilic interactions 19 ,200 but without the ability to specify the placement of
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many different microtissues relative to one another. One potential method for controlled
assembly of heterostructures would be to incorporate the specificity of biomolecular
interactions with surface templating to direct assembly. This approach could allow for scalable
patterning of multiple cell types into arbritrary architectures with high precision.
In this chapter, we harness the well-characterized molecular recognition capabilities of
DNA to achieve rapid templated assembly of multiple microtissue types (Fig. 2.1). This method
is enabled by the high-throughput production of spherical cell-laden microtissues from a
microfluidically-derived, monodispersed emulsion of a photocurable hydrogel. Cell-laden
microtissues are derivatized with single-stranded oligonucleotides and integrated with custom
DNA microarray templates. Orthogonal DNA sequences are used to specify the assembly of
multiple cell types over large (-mm) length scales with high capture efficiency. This fusion of
"bottom-up" (templated assembly) and "top-down" (microfluidics and robotic spotting)
approaches allows for unprecedented control over mesoscale tissue microarchitecture and
exemplifies the potential of integrating disparate fabrication strategies.
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Figure 2.1. Schematic of microtissue encapsulation, functionalization, and DNA-templated
self assembly. Cells are injected with a photopolymerizable hydrogel prepolymer into a high-
throughput microfluidic encapsulation device. Droplets of the cell-prepolymer mixture are
exposed to UV on-chip to form streptavidin-containing microtissues which are then coated with
5'-biotin terminated oligonucleotides. Encoded microtissues containing different cell types are
seeded on a DNA microarray template which directs the binding of microtissues to specific
spots on the templating surface, attaining sequential DNA-templated patterning of cell-laden
microtissues.
2.2 Materials and Methods
Device fabrication
Microfluidic device masters were fabricated on 4 inch silicon wafers using standard
photolithographic methods, with SU-8 2050 photoresist (Microchem, MA) spin coated at 1200
rpm to create 125 iim tall features. Masters were coated with trichloro perfluorooctyl silane
(Sigma-Aldrich) for 1 hr in a vacuum dessicator prior to casting polydimethylsiloxane (PDMS,
Dow Coming) devices. Cured devices with inlet holes made by a 20G dispensing needle
(McMaster-Carr) were bonded to glass slides following air plasma treatment. In order to ensure
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a hydrophobic surface for droplet generation, Aquapel (PPG Industries) was briefly injected
into the device and flushed out with nitrogen.
Ligand conjugation
Acrylate-PEG-RGDS peptide was prepared as previously described. 14 To conjugate
streptavidin with acrylate groups, streptavidin was dissolved in 50 mM sodium bicarbonate
(pH 8.5) at 0.8 mg/ml. Amine-reactive acrylate-PEG-SVA (3.4 kDa, Laysan) was added at a 25:1
molar ratio and allowed to react with the protein at room temperature for 2 hours. Conjugated
acrylate-PEG-streptavidin was purified from unconjugated PEG by washing in PBS with a
30,000 MWCO spin filter (Millipore). The acrylate-PEG-streptavidin conjugate was then
reconstituted to 38 jM streptavidin in PBS, sterile filtered, and stored at -20'C.
Microtissue polymerization
Irgacure-2959 initiator (Ciba) was dissolved at 100 mg/ml in n-vinyl pyrrolidinone
accelerator (Sigma-Aldrich) to make photoinitiator working solution. The basic 2x concentrated
prepolymer solution consisted of 20% w/v poly(ethylene glycol) diacrylate (PEG-DA, 20kDa,
Laysan) and 2% v/v of photoinitiator working solution. Additional prepolymer ingredients
included 38 1 M of acrylate-PEG-streptavidin conjugate, 10 mM acrylate-PEG-RGDS, and/or 1%
v/v of fluorescent microspheres (2% solids, Invitrogen) as markers.
The final 2x prepolymer solution was injected into the microencapsulation device in
parallel with, for cell-free microtissues, a 1:1 diluting stream of PBS. Syringe pumps were used
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to control the flow rates of the aqueous phases and the oil phase, which consists of the perfluoro
polyether, Fomblin (Y-LVAC, Solvay Solexis), with 0-2 w/v% Krytox 157 FSH surfactant
(DuPont). Prepolymer droplets were gelled on-chip by exposure to 500 mW/cm 2 of 320-390 nm
UV light (Omnicure S1000, Exfo) for an approximately one second residence time under typical
flow conditions. Cell-free microtissues were collected in handling buffer (PBS with 0.1% v/v
Tween-20), allowed to separate from the oil phase, and washed on a 70 pm cell strainer to
remove un-polymerized solutes.
Bead hybridization
To stain for the surface-availability of ssDNA bound on microtissues, 1 Prm NeutrAvidin
biotin-binding beads (yellow-green, Invitrogen) were coated with the complementary 5'-biotin-
DNA (IDT). The original suspension of beads (1% solids) was diluted 1:10 with BlockAid
blocking solution (Invitrogen), sonicated for 5 minutes, and then incubated with a final
concentration of 4 jM 5'-biotin-DNA for 1 hour at room temperature. Beads were then washed
three times in PBS by centrifugation at 2000xg. DNA-functionalized microtissues were
incubated overnight on a room-temperature shaker with coated beads resuspended to 0.1%
solids in BlockAid.
Microarray spotting
Microarray templates were printed in-house using a contact-deposition DNA spotter
(Cartesian Technologies) with a 946MP10 pin (Arrayit). Complementary pairs of single-
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stranded oligonucleotides used to functionalize microtissues and template their assembly are
listed below and consisted of a poly-A linker followed by a heterogeneous 20 nucleotide
sequence. The 20-nucleotide binding region of A and A' are complementary, B and B', etc.
Sequences were modified with 5'-amino groups for microarray spotting, and 5'-biotin groups
for microtissue functionalization.
Label Sequence
A 5'- AAAAAAAAAAGCCGTCGGTTCAGGTCATA-3'
A' 5'- AAAAAAAAAAATATGACCTGAACCGACGGC-3'
B 5'- AAAAAAAAAAAGACACGACACACTGGCTTA-3'
B' 5'-AAAAAAAAAATAAGCCAGTGTGTCGTGTCT-3'
C 5'-AAAAAAAAAAGCCTCATTGAATCATGCCTA-3'
C' 5'-AAAAAAAAAATAGGCATGATTCAATGAGGC-3'
D 5'-AAAAAAAAAATAGCGATAGTAGACGAGTGC-3'
D' 5'-AAAAAAAAAAGCACTCGTCTACTATCGCTA-3'
5'-amino oligonucleotides (IDTDNA) for templating were dissolved in 150 mM
phosphate buffer (pH 8.5) at concentrations up to 250 VM, and spotted on epoxide coated slides
(Corning) at 70% RH. Patterned slides were then incubated for 12 hours in a 75% RH saturated
NaCl chamber, blocked for 30 minutes in 50 mM ethanolamine in 0.1M Tris with 0.1% w/v SDS
(pH 9), and rinsed thoroughly with deionized water.
DNA-directed assembly
Microtissues containing PEG-streptavidin were incubated with 1 nmol of 5'-biotin
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oligonucleotides per 10 ul of packed microtissues for one hour at room temperature or
overnight at 4'C. Un-bound oligonucleotides were removed by washing microtissues on a 70
1IM cell strainer or using 100,000 MWCO spin filters. Multi-well chambers (ProPlate, Grace Bio-
Labs) were assembled over templating slides, and DNA-functionalized microtissues were
seeded in a concentrated suspension over the microarray patterns. Microtissues quickly settled
into a monolayer, which was visually confirmed under a microscope. Unbound microtissues
were washed off the template by gently rinsing the slide with several ml of handling buffer.
Capture efficiency was quantified by the average capture density over replicate spots on a slide,
divided by the average seeding density of settled microtissues in a 4x microscope field of view.
Percent of maximum packing fraction was calculated as the ratio of capture density to the
theoretical density of close-packed circles.
Cell culture
J2-3T3 fibroblasts were cultured in Dulbecco's Modified Eagle Medium (DMEM,
Invitrogen) with 10% bovine serum (Invitrogen), 10 U/ml penicillin (Invitrogen), and 10 mg/ml
streptomycin (Invitrogen). TK6 lymphoblasts (suspension culture) and A549 lung
adenocarcinoma cells were cultured in RPMI 1640 with L-glutamine (Invitrogen) and 10% fetal
bovine serum (Invitrogen), 10 U/ml penicillin, and 10 mg/ml streptomycin. All cells were
cultured in a 5% CO2humidified incubator at 37'C.
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Cell encapsulation
Prior to encapsulation, adherent cells (J2-3T3 and A549) were detached with 0.25%
trypsin-EDTA (Invitrogen). Cell pellets were resuspended at cell densities between 10x10 6
cells/ml and 30x10 6 cells/ml in an isopycnic injection medium consisting of 20% v/v OptiPrep
(Sigma-Aldrich) in serum-free DMEM. Isopycnic cell suspensions were injected into
microencapsulation devices in place of the diluting stream of PBS, along with 2x prepolymer
solution. Gelled microtissues were collected and handled in culture media. To assess cell
viability after 3 hours, microtissues stained with calcein AM (1:200, 1 mg/ml in DMSO,
Invitrogen) and ethidium homodimer (1:400, 1 mg/ml in DMSO, Invitrogen) for 15 minutes at
37'C. Alternatively, microtissues for DNA-templated assembly were marked with CellTracker
Green CMFDA (1:200, 5 mg/ml in DMSO, Invitrogen) or CellTracker Blue CMAC (1:200, 5
mg/ml in DMSO, Invitrogen) for 1 hour at 37'C.
Imaging and visualization
Images were acquired with a Nikon Ellipse TE200 inverted fluorescence microscope, a
CoolSnap-HQ Digital CCD Camera, and MetaMorph Image Analysis Software. NIH software
ImageJ was used to uniformly adjust brightness/contrast, and pseudocolor, merge, and quantify
images. Confocal images were acquired with an Olympus FV1000 multiphoton microscope and
Olympus Fluoview software. NIS-Elements software was used to pseudocolor and reconstruct
maximum intensity, slice, and volume views.
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2.3 Results and Discussion
2.3.1 High-throughput microtissue fabrication
One factor restricting the application of bottom-up assembly to tissue engineering has
been the low throughput of typical microtissue fabrication approaches to date, many of which
are batch processes. 1 49 , 194, 201 We first sought to design a microfluidic chip to rapidly produce
uniform microtissues. Droplets generated by flow focusing of aqueous/oil phases are
monodisperse and amenable to photopolymerization.2 02 Thus, we fabricated a device to shear
photopolymerizable poly(ethylene glycol) diacrylate (PEG-DA) prepolymer containing cells
into droplets in oil for downstream gelation by UV-light (Fig. 2.2a). Concentrated pre-polymer
was injected into the microencapsulation device as a separate stream from the cell suspension
(PBS for cell-free microtissues), where the two aqueous streams were designed to meet before
reaching a flow-focusing junction (Fig. 2.2b). With a 60 iam nozzle, shear forces were sufficient
to disperse the aqueous combination into droplets that passed through a corrugated serpentine
channe 203 to thoroughly mix the cell-prepolymer solution (Fig. 2.2c). The droplets were then
polymerized by UV irradiation for 1 second during transport to the outlet. Resulting
microtissues were uniformly spherical and monodisperse (Fig. 2.2d). We observed that by
adjusting aqueous vs. oil phase flow rates (Fig. 2.2e) and oil-phase surfactant concentrations
(Fig. 2f), we could finely control droplet diameter, and hence microtissue size, between 30-120
mIr.
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At a typical prepolymer flow rate of 200 ul/hr, our device was capable of achieving a
production throughput of 6000 microtissues/min (~10 5/hr), two orders of magnitude faster than
other continuous systems such as stop-flow lithography 15 6 (~10 3 particles/hr) or batch fabrication
processes.149 Microtissue fabrication by microfluidic droplet photopolymerization provides
precise control over microtissue shape and size, whereas photolithographic 149 and molding 94 196
techniques do not produce spherical gels and can suffer from resolution limits. Planar
microtissue surfaces tend to adhere non-specifically to hydrophilic surfaces due to the high
water content (>90%204) of the hydrogel material, whereas the low contact area of spherical
microtissues reduces capillary adhesion during both handling and assembly. Droplet-based gels
have previously been made using agarose 20 1 or alginate; 14 here, we chose a PEG hydrogel
material for its biocompatibility and biochemical versatility. PEG-diacrylate hydrogels have
high water content, are non-immunogenic and resistant to protein adsorption, and can be easily
customized with degradable linkages, adhesive ligands, and other biologically or chemically
active factors. 13 1
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Figure 2.2. Microencapsulation device. (a) Overview of device showing two aqueous input
streams (red, blue) dispersed by shear flow from an oil stream into droplets that mix (purple)
and travel down the UV-exposure channel. (b) Prepolymer (2x concentrated) and a cell
suspension meet and flow into a 60 tm droplet generating nozzle. Vertical columns on either
side of the channel provide visual references (50-100 tm below, 100-150 tm above) for real-time
adjustment of droplet size. (c) Droplets pass through a bumpy serpentine mixer section to
thoroughly disperse cells in prepolymer and are then polymerized by UV irradiation from a
curing lamp. (d) Microtissues collected from the device (6000/min) are spherical and
monodisperse. (e) Microtissue size is controlled by the relative flow rates of the combined
aqueous phase (Qr) and the continuous oil phase (Qo), and increases with prepolymer:oil flow
ratio. (f) Adding small amounts of Krytox 157 FSH fluorosurfactant into the oil decreased
droplet diameter at all flow ratios, allowing higher prepolymer flow rates for a given
microtissue size.
2.3.2. Microtissue functionalization with surface-encoding DNA
Having established a method to uniformly produce microtissues, we next sought to
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modify our microtissues with streptavidin for binding biotinylated DNA. To accomplish this,
streptavidin was incubated with amine-reactive acrylate-PEG-SVA (3.4 kDa). Following
purification, the acrylate-decorated streptavidin was then mixed into the prepolymer and
covalently bound into the acrylate-PEG-acrylate hydrogel network during gelation by acrylate
polymerization (Fig. 2.3a). Cell-free PEG-SA microtissues containing conjugated acrylate-PEG-
streptavidin were stained to verify biotin-binding capacity using biotin-4-fluorescein.We also
confirmed the surface-availability of streptavidin with an anti-streptavidin antibody , which
was size restricted to only the surface of the microtissue (~7 nm mesh size2 4) . Both biotin
fluorescence and antibody staining intensities increased with the volumetric concentration of
conjugated streptavidin (Fig. 2.3b).
With streptavidin incorporated into the hydrogel network, we were able to encode the
microtissues post-polymerization with 5'-biotin terminated oligonucleotides (Fig. 2.3c).
Streptavidin-biotin based DNA-functionalization of microtissues is simple, modular, and
cytocompatible. Post-polymerization encoding of microtissues with biotin-DNA avoids UV
damage that would occur by pre-mixing acrylated-DNA into the prepolymer,20 ,2 o7 and allows
the same batch of microtissues to be labeled after culture in various conditions. Other
bioconjugation methods exist to modify hydrogel networks post-encapsulation, such as
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Figure 2.3. Microtissue functionalization with streptavidin and DNA. (a) The primary
hydrogel component, acrylate-PEG20k-acrylate macromonomer, was mixed with conjugated
acrylate-PEG-streptavidin (0-2 mg/ml) before photo-initiated free radical polymerization,
forming a hydrogel network that is decorated with pendant streptavidin proteins. (b) PEG-
streptavidin microtissues stained with biotin-4-fluorescein, which can freely diffuse through the
hydrogel network, and anti-streptavidin IgG which is restricted to the surface of the
microtissues. The intensity of biotin-4-fluorescein staining increased linearly with the bulk
concentration of covalently-bound streptavidin, while antibody stains for surface concentration
increased only as a power of bulk concentration. (c) PEG-SA microtissues are further
functionalized with biotin-ssDNA. The availability of this ssDNA to hybridize with a
templating surface was tested using 1 pm fluorescent beads coated with DNA. (d) Microtissues
with the appropriate complementary sequence were coated with hybridized beads. No beads
hybridized to control-sequence microtissues, which remained dark in the green channel and
showed only encapsulated marker beads in the phase image.
maleimide or NHS chemistries20s but often require reaction conditions that are incompatible
with maintaining the viability of encapsulated cells. To ensure that DNA bound to microtissues
using the streptavidin-biotin interaction was available to hybridize with DNA displayed on a
surface, we incubated DNA-encoded microtissues with 1 jam polystyrene beads coated with the
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complementary oligonucleotide (Fig. 2.3c). After washing to remove non-specifically bound
material, microtissues encoded with the complementary sequence were thoroughly coated with
beads visible as bright, punctate spots (Fig. 2.3d). Conversely, beads did not specifically
hybridize to control microtissues (Fig. 2.3d). In order to maximize bead-microtissue
hybridization, we investigated conjugating acrylate-PEG-SVA to streptavidin at several molar
ratios (Fig. 2.4). As expected, microtissues incorporating streptavidin with few acrylate
pendants (10:1 molar ratio, mobility shift assay) did not promote bead hybridization as
effectively as streptavidin modified with a higher number of acrylate groups (25:1 to 50:1 molar
ratio), which was used for all further studies. Gels with over-decorated streptavidin (1000:1
molar ratio) were also not as efficient in mediating bead-microtissue hybridization, suggesting
that overmodification and/or steric hindrance plays an important role in DNA-binding capacity.
Acryl-PEG3400-SVA :Streptavidin molar ratio
1000x 200x 100x 50x 25x 1Ox unmod
-250 kD
-150 kD
-100 kD
-75 kW
-50 kW
-37 kD
Biotin:Streptavidin
binding capacity: >84 2. 7 3.02 3.21 3.71
(HABA ass
Figure 2.4. Optimization of acrylate-PEG-streptavidin conjugation. Non-denaturing PAGE gel
(top) of purified products from varying molar ratios of reactants. At low ratios, discrete bands
of protein with 1-5 modified amines are visible. At higher ratios, streptavidin is overmodified
and biotin-binding capacity is significantly reduced. Reaction conditions of interest were further
tested by incorporating products into microtissues, binding biotin-DNA, and staining by
hybridization with DNA-coated beads (bottom).
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2.3.3 Binding efficiency and specificity of DNA-templated assembly
Having shown that cell-free microtissues can be coated with DNA and hybridize
specifically to complementary beads, we next investigated the potential of microtissue assembly
into mesoscale patterns determined by an encoded template. To create such a template, we
spotted increasing concentrations of DNA (sequence A') onto a functionalized glass slide using
conventional microarray technology. DNA-functionalized microtissues (A; containing green
marker beads) were allowed to settle onto microarray slides from suspension, at which time
non-hybridized microtissues were gently washed off the slide. The number of microtissues
bound to templating array spots increased with higher spotting concentrations of templating
ssDNA (Fig. 2.5a), plateauing at 250 jM, an order of magnitude higher than typical epoxy-
silane based microarray spotting concentrations. Spots were fully covered by microtissues at
this highest DNA density. To determine the capture efficiency, we seeded microtissues at
varying densities (microtissues per mm 2, Fig. 2.5b). At contact-limited (hexagonally close-
packed) seeding concentrations, we achieved 100% capture efficiency, indicating that if a
microtissue settled onto a complementary spot, hybridization and binding would occur.
Similar efficiencies have been observed during the DNA-templated assembly of
materials ranging in scale from molecules to nanoparticles to single cells'95 , 2.9214. Until now,
DNA-templated assembly has not been extended to larger units such as microtissues (100 jam),
which present unique challenges in mass transport.215 At these mesoscopic scales, gravity and
friction become important factors in the ability of DNA-coated surfaces to sufficiently interact.
During washing steps, stronger viscous drag forces on the microtissues necessitate a large
number of hybridization bonds between the microtissues and templating surface to overcome
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microtissue removal. Here, to compensate for microtissue size, we optimize microtissue DNA
functionalization and template spotting to achieve high DNA surface densities, enabling the
first demonstration of large structure DNA-templated assembly.
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Figure 2.5. Capture efficiency and specificity of DNA-directed microtissue assembly. (a)
Number of DNA-functionalized microtissues containing fluorescent beads as markers captured
on microarray spots with increasing spotting concentration of complementary oligonucleotide.
(b) Quantified assembly results from microtissues seeded over an array of complementary spots
at low, medium (shown on the left), and high (close-packed) % surface coverage. Control arrays
of non-complementary spots remained blank. (c) Three-color (RGB) microtissue assembly using
a set of orthogonal oligonucleotide sequences: B (red), C (green), and D (blue). Microtissues
contain encapsulated marker beads. (d) Quantified percentages of microtissues on target spots
(1 column) vs. off-target spots (2 columns). (e) MIT logo assembled in microtissues of C (green)
and D (blue), and (f) photograph of templating slide illustrating scale of assembled microtissue
patterns. (g) Maximum intensity projection and (h) volume reconstructions from multi-photon
scans of 3D microtissue structure formed by templating a first layer of microtissues (B, green)
and then assembling a second layer of complementary microtissues (B', red).
During our assembly process, minimal microtissue binding was observed between spots
and on non-complementary templating spots (Fig. 2.5b), which was largely made possible by
our control over microtissue shape. This low background binding allowed us to sequentially
pattern multiple microtissue types, each encoded with an orthogonal oligonucleotide sequence,
with over 90% specificity (Fig. 2.5c, d) and across large areas in under 15 minutes (Fig. 2.5e, f).
Furthermore, we were able to build 3D structures (Fig. 2.5g, h) by filling template spots (B')
with a layer of microtissues (B), and then seeding a second layer of complementary microtissues
(B') that bind on and around microtissues in the first layer. Together, these experiments
demonstrate the ease of achieving organizational control at macroscopic length scales by
microtissue assembly.
2.3.4 DNA-templated assembly of multicellular tissue constructs
In order to apply DNA-templated patterning to the assembly of multicellular constructs,
we next focused on encapsulating cells into uniform and highly viable cell-laden microtissues.
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To improve the consistency of cell encapsulation (Fig. 2.6), we increased the specific gravity of
our cell suspensions to prevent cell settling during injection. We chose a density gradient
medium (OptiPrep), based on an iodinated small molecule, that increases specific gravity
without affecting viscosity or cross-linked hydrogel network density, and easily diffuses out of
the polymerized microtissues. With these changes, we attained cell encapsulation matching a
Poisson distribution (Fig. 2.7b). In addition, we replaced the hydrocarbon oil phase with an
oxygen-permeable fluorocarbon oil (Fomblin) to allow immediate quenching of excess free
radicals post-UV exposure. 216 Notably, using fluorocarbon oil, cells were able to tolerate a wide
range of total UV exposures (mJ/cm 2 ) while maintaining >90% viability (Fig. 2.7c). As a result of
these changes, several adhesive and suspension cell lines, including adherent mesenchymal
(fibroblasts), nonadherent mesenchymal (lymphoblasts) and adherent epithelial
(adenocarcinoma), were uniformly encapsulated into microtissues with consistently high
viability (Fig. 2.7a). Variations in average viability between cell types (e.g. J2-3T3 vs. TK6) could
be due a number of cell type differences including susceptibility to DNA damage.2 17 For cell
lines sensitive to UV, photoinitiators in the visible-light range could be substituted into our
material system.2 1 s
These are many advantages associated with patterning cellular microtissues rather than
single cells.2 a 212 Firstly, cells can be encapsulated in a modular scaffold with customized ECM
molecules (e.g. RGDS) to promote certain phenotypes. As an example, we added acrylated
RGDS peptide to the prepolymer during fibroblast encapsulation. By Day 2 post-encapsulation,
fibroblasts began spreading within these adhesive microtissues (Fig. 2.7d, Fig. 2.8). Secondly,
microtissues containing one cell type can be first cultured separately to stabilize homotypic
43
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Figure 2.6. Distribution of cell encapsulation numbers within microtissues. (a) Prior to
process modifications, cells that were suspended in prepolymer settled within tubing between
the syringe and the device, resulting in oscillating cell density reaching the nozzle and an
uneven number of cells per microtissue. (b) When cells are injected in an isopycnic medium,
and as a separate stream from concentrated prepolymer, the distribution narrowed to the
Poisson limit.
interactions before they are self-assembled with other microtissues to activate heterotypic
interactions. For instance, when cultured for several days, adenocarcinoma cells encapsulated
from a single-cell suspension formed multicellular spheroids (Fig. 2.7e). In addition, encoding
DNA is bound to the hydrogel scaffold rather than directly onto the cell membrane,2 n,2 12 where
covalently bound ligands may be susceptible to recycling or may potentially modify cell
function. Encoded microtissues can remain in assembled patterns for an extended period of
time without additional measures for immobilization (e.g. embedding in agarose195), and then
removed for further culture, isolation, and biochemical analysis. 149 DNA provides a way for
programmed detachment via dehybridization (e.g. competitive binding with free ssDNA) or
cleavage (e.g. restriction enzymes).211 Alternatively, patterned microtissues could be stabilized
into a contiguous tissue by a secondary hydrogel polymerization 200 or cell adhesion between
microtissues to form 3D sheets for implantation (Fig. 2.9).
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Figure 2.7. Cell encapsulation and microtissue culture. (a) Rat fibroblast (J2-3T3) and human
lymphoblast (TK6) cell lines uniformly encapsulated within microtissues and stained for
viability. (b) Histogram of J2-3T3 distribution within microtissues and comparison to optimal
Poisson statistics. (c) Viability of J2-3T3 and TK6 cells three hours post-encapsulation at
increasing % UV overexposure past the minimum intensity required to fully polymerize
microtissues. (d) J2-3T3 cells attached and spread within microtissues decorated with RGDS
peptides. (e) Human lung adenocarcinoma (A549) cells aggregated to form multicellular tumor
spheroids within microtissues. (f) Microtissues encapsulating either J2-3T3 (CellTracker Green)
or A549 cells (CellTracker Blue) were self-assembled into composite hexagonal clusters.
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Finally, to demonstrate DNA-templated positioning of microtissues containing distinct
cell types into pre-defined patterns, we encapsulated adenocarcinoma cells (blue) and
fibroblasts (green) into separate microtissues and encoded them with orthogonal DNA
sequences (C and D respectively). These microtissues were then seeded onto an array printed
with hexagonal clusters of complementary DNA (C' centered within 6 spots of D'), forming co-
cultures of the two cell types representative of a tumor nodule surrounded by stromal cells (Fig.
2.7f). Multicellular constructs patterned using this method could be relevant model systems for
studying cancer-stroma interactions in 3D. Notably, although DNA-templated microtissues are
patterned on a 2D template, cells are encapsulated and respond to a locally 3D
microenvironment, e.g. developing into tumor spheroids (Fig. 2.7e) rather than growing as a 2D
monolayer. 2 Heterotypic signaling from stromal cells has been shown to contribute to tumor
invasion and metastasis. 186 The combination of precise spatial control, similar to that achieved in
2D,146 but with a 3D environment, will be critical toward elucidating such cell signaling
mechanisms.
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Figure 2.8. Multi-photon images of fibroblast spreading within RGDS microtissues. (a)
Maximum intensity projection and (b) slice images of J2-3T3 fibroblasts spreading on Day 4
post-encapsulation. Red: actin (phalloidin), green: hydrogel (biotin-4-fluorescein), bright-green:
nuclei (Hoecht).
Figure 2.9. Fibroblast-laden, RGD-decorated microtissues cultured in close contact and in the
presence of non-encapsulated fibroblasts. Contiguous microtissue-assembled structures linked
by adherent cells formed by D1 post-encapsulation.
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2.4 Conclusion
We have described a method to organize multiple cell types within a 3D
microenvironment that integrates the top-down patterning of a DNA microarray template with
the bottom-up assembly of DNA-encoded, cell-laden microtissues. This is the first
demonstration of microtissue assembly that is directed by specific biomolecular interactions.
The speed and scalability of the assembly process is compatible with DNA templates that can be
fabricated by other top-down techniques, such as microfabrication and micro-contact printing,
for a diverse range of features and patterning resolution. The programmable molecular
interaction of DNA to direct assembly has the potential to be extended to even larger sets of
encoding sequences to create more complex heterogeneous structures. The ability to precisely
control cell-cell interactions (e.g. cancer-stromal cell, hepatic-nonparenchymal cell) via
microfluidic cell encapsulation and DNA-templated microtissue assembly provides a unique
opportunity to increase our fundamental understanding of complex diseases or to construct
highly functional tissue-engineered implants.
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Chapter 3: Flow Analysis of Microenvironmental Effects
on Tumor Proliferation
3.1 Introduction
The cellular microenvironment, which includes soluble signals such as growth factors
and hormones, as well as insoluble signals such as cell-cell and cell-matrix interactions,
regulates key aspects of healthy and diseased tissue functions. This observation is particularly
relevant in cancer, where the microenvironment has been shown to play a critical role in tumor
development, metastasis, and drug resistance- 4 1 . For example, drug resistance in tumor cells
can be modulated by the addition of stromal cells219 as well as culture in 3D spheroidss",", 10 1, 220
or encapsulation in synthetic or natural extracellular matrix (ECM)s2,221. The unique phenotypes
demonstrated in 3D cell culture are due to changes in a variety of microenvironmental factors,
including altered cell-cell contacts, diffusion of nutrients and signaling mediators92, and integrin
ligation with growth factor pathway crosstalk3, 92,22 2,223. Because cellular behavior is dependent
on architectural cues, studying microenvironmental influences on cancer progression in 3D
could offer unique opportunities. Animal models inherently include critical
microenvironmental cues and three-dimensional tissues, but they lack the throughput required
for many applications. In vitro tumor models that allow us to control microenvironmental cues
specifically in a 3D context may provide a complementary tool to bridge 2D and in vivo studies,
and may more accurately predict in vivo cancer progression and response to therapeutics.
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Systematic exploration of microenvironmental cues for many applications, such as drug
screening, requires high-throughput platforms that incorporate rapid production and analysis
of combinatorial 3D tissue constructs. Microscale versions (100-500 tam) of cell-laden gels
("microtissues") can incorporate a range of co-encapsulated stromal and external diffusible
cues. Microtissues have been fabricated by various methods including photolithographyis, 224,
micromoldings 2, and emulsification 15 7, but the majority of these techniques are limited in
throughput or result in extremely polydisperse microtissue populations. A promising method
for high-speed production of microtissues is droplet-based cell encapsulation, wherein a cell-
prepolymer mixture is emulsified on-chip by a shearing oil stream and polymerized while in
droplets22 . This process has been demonstrated for a variety of ECM materials, including
polyethylene glycol (PEG)225 , alginate1 41, 226, collagen 22 7, and agarose1 39 , is compatible with a
range of cell types (>90% encapsulation efficiency), and rapidly produces large numbers of
monodisperse microtissues (6000 gels/min). Although droplet devices facilitate high throughput
microtissue fabrication, to date analysis of droplet-derived microtissues has relied on serial
imaging. While imaging is information-rich, it is labor-intensive and would become a bottleneck
in the context of high throughput screening, especially with large numbers of microtissues. One
solution for increasing analytical throughput is the use of an in-flow sorting and analysis
system, similar to flow cytometry, that can analyze and sort microtissues on multiple
parameters, such as cell density, size and composition based on time-of-flight, extinction,
absorbance, and fluorescence. The capability of such a system to quantify fluorescent reporter
expression has been demonstrated using microtissues that represent stages of liver
development and disease (n>102-103, fabricated by photolithography)149 . Combining high-
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speed in-flow analysis with a high throughput microtissue fabrication would produce an ideal
system for combinatorial microenvironmental modulation that could be used in high-
throughput biology and screening cancer therapeutics.
In this chapter, we combine microfluidic cell encapsulation with large-particle flow
analysis to present an integrated platform for studying the effects of microenvironmental cues
(cellular, ECM, growth factors, drugs) on tumor cell proliferation in various 3D contexts. To
specifically interrogate the impact of various microenvironmental inputs, tumor and stromal
cells were incorporated into droplets at high densities and cell-ECM interactions were
controlled by physically entrapping full-length matrix proteins within the encapsulating
hydrogel. Furthermore, we exploited the native stochasticity generated during microfluidic
encapsulation to generate diverse subpopulations of microtissues that contain varied degrees of
homotypic and heterotypic interactions, and we isolated those subpopulations using flow
sorting to generate highly defined microenvironments. As the primary readout, sorted
populations cultured with and without exposure to a panel of soluble factors were re-examined
via flow analysis to rapidly record large-scale population data (n>500 events). Finally, we
applied this platform to investigate the influence of TGF-P signaling, which is known to be
strongly context-dependent and can be either tumor suppressing or cancer promoting, on
tumor cell proliferation. We report the outcome of a proof-of-principle drug candidate screen on
KrasLSL-G12DI+;p53loxflox mouse non-small-cell lung cancer (NSCLC) derived cell lines16 . This screen
revealed differing sensitivities of these particular lines to TGF-p signaling in 3D that were not
observed in 2D. Our ability to study tumor biology and to develop effective new therapies will
require systematic study of tumor cells within a microenvironmental context. The platform that
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we have developed provides a high-throughput method to study drug response and tumor
biology within highly-defined microenvironmental niches.
3.2 Materials and Methods
Tunable microtissue synthesis
Microfluidic device fabrication and cell encapsulation have been described previously22 .
Briefly, cells or a mixture of cells were injected into the device as an isopycnic suspension and
mixed on-chip with 2x concentrated photopolymerizable polyethylene glycol prepolymer. For
microtissues functionalized with matrix proteins, collagen I (rat tail, BD Biosciences), fibronectin
(human, Millipore), or laminin (murine, Sigma) were included in the concentrated prepolymer
at 40 pg/ml. The combined aqueous stream, consisting of 10% (w/v) PEG-DA (20kDa, Laysan),
0.1% (w/v) Irgacure-2959 (Ciba), 1% (v/v) n-vinyl pyrrolidone (Sigma-Aldrich), up to 20 jg/ml
ECM proteins, and up to 50x106 cells/ml, was sheared into droplets by fluorocarbon oil at a
flow-focusing junction. Downstream, ultraviolet light (Exfo Omnicure, 500 mJ/cm 2) was used to
crosslink droplets into spherical cell-laden hydrogels. Microtissue size was controlled by
adjusting the oil/prepolymer flow rates (typically 800 l/hr and 200 l/hr, respectively) to
produce monodisperse microtissues between 50-120 tm that were collected and washed in
media before preliminary analysis and sorting.
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Large particle flow cytometry
Microtissue reporter and cell fluorescence levels were quantified using a complex object
parametric analyzer for handling 500 tm objects (COPAS Select, Union Biometrica) according
to the manufacturer's instructions. Samples were first gated by Time of Flight (size) vs.
Extinction (optical density) to exclude cell debris and aggregates. Gated microtissues were then
analyzed for Green (gain: 300) and FarRed (gain: 850, -50% Green compensation) fluorescence
and sorted into multiwell plates filled with media. Post-sorting, microtissues were washed in
PBS by filtering through 40 tm nylon strainers, resuspended in media, and transferred to low-
attachment plates for culture and treatment. COPAS data was re-gated and processed using
custom MATLAB code.
Cell culture
Murine cell lines 393T5 and 394T4 have been previously described 16. Briefly, tumors
were initiated in KrasLSL-G12D/+;p53loxflox mice with intratracheal lentiviral-Cre vectors. Tumors were
then excised from the mice, enzymatically digested, and subsequently plated onto tissue culture
treated plastic to generate cell lines. Cell lines were transfected with ZsGreen 33 and
subsequently cultured in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) with 10%
fetal bovine serum (Invitrogen), 10 U/ml penicillin (Invitrogen), and 10 mg/ml streptomycin
(Invitrogen). J2-3T3 fibroblasts were cultured in DMEM with 10% bovine serum (Invitrogen), 10
U/ml penicillin, and 10 mg/ml streptomycin. All cells were cultured in a 5% CO2 humidified
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incubator at 37*C. To label fibroblasts prior to encapsulation, cells were detached with 0.25%
trypsin-EDTA (Invitrogen) and resuspended in PBS. CellTracker Far Red DDAO-SE (Invitrogen,
1.18 mM in DMSO) was added to the cell suspension (1:625 dilution) and incubated for 45
minutes at 37*C. The cell pellet was then centrifuged, washed, and either re-plated (the dye was
stable for several days) or used immediately.
Growth factors and inhibitors
Microtissues were cultured in 10% serum media and treated with growth factors EGF,
TGF-P, VEGF, or HGF (R&D Systems) at 50 ng/ml. Small molecule inhibitors were dosed into
the microtissue media to a final 10 tM in 0.2% DMSO: SB525334 (Tocris), SJN2511 (Tocris),
LY2157299 (Selleckchem), dorsomorphin dihydrochloride (Tocris), DMH-1 (Tocris), or GW5074
(Tocris).
Tumor cell proliferation in 2D
393T5 cells were detached with 0.25% trypsin-EDTA (Invitrogen) and replated at a
density of 4000 cells/well into 96-well plates. One day post-seeding and daily thereafter, fresh
media and drugs were added and ZsGreen fluorescence was measured using a microplate
reader (Molecular Devices).
Microtissue staining and visualization
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Live microtissues were imaged directly for ZsGreen-labeled tumor cell line fluorescence
or CellTracker Far Red-labeled fibroblasts. Alternatively, microtissues were fixed and
permeabilized in order to count embedded cell nuclei. To bypass any difficulties preserving
ZsGreen protein fluorescence after fixation, microtissues containing ZsGreen-labeled cells were
additionally incubated with CellTracker Green CMFDA (Invitrogen) prior to being fixed (4%
paraformaldehyde). Microtissues were then permeabilized (0.05%Triton X-100), and stained
with Hoechst 33342 (Invitrogen). Images were acquired with a Nikon Ellipse TE200 inverted
fluorescence microscope, a CoolSnap-HQ Digital CCD Camera, and MetaMorph Image
Analysis Software. NIH software ImageJ was used to uniformly adjust brightness/contrast,
pseudocolor, and merge images.
Statistical analysis
Data are presented as mean ± SEM, except for microtissue cell counts which are
described as mean ± standard deviation. Samples were compared using one-way ANOVA, with
p-values of <0.05 considered statistically significant.
3.3 Results and Discussion
3.3.1 Platform design
Many techniques for 3D tumor culture have been developed, including encapsulating
cells within bulk hydrogels of specific scaffold materials, to control stiffness and ECM
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composition. However, these systems do not miniaturize readily for high-throughput studies,
especially in situations when cells or reagents are limiting. Further, readouts for larger gels
often require imaging15, which is slow and laborious, or biochemical assays that provide only a
global measurement averaged over many local microenvironments. Alternatively, formation of
3D tumor spheroids 7 has been useful in elucidating the importance of architecture on tumor
phenotype. Unfortunately, these niches do not incorporate the kind of microenvironmental
control that is available through tuning the physical and biochemical properties of engineered
scaffolds.22 s
To generate homogeneous populations of defined microtissues for evaluating
proliferative potential under designated microenvironmental and soluble cues, we established
an experimental workflow that can be divided into five phases (Fig. 3.1). First, fluorescently
labeled tumor cells are microfluidically encapsulated with the desired combination of stromal
cells or ECM into synthetic 3D microtissues (Fig. 3.1a). We chose poly(ethylene glycol)
diacrylate (PEG-DA, 20kDa) as the hydrogel material because it provides a biocompatible, non-
stimulatory background, and unlike other scaffold materials, such as collagen or agarose, PEG
can be chemically decorated with integrin binding peptides 1 4, proteins 229, and other ligands13 1.
In the second phase, a large-particle flow analyzer is used to initially characterize freshly
generated microtissues in multiple channels of embedded-cell fluorescence (Fig. 3.1b). Defined
populations of microtissues are selected and sorted by tumor and/or stromal cell density (Fig.
3.1c). These steps are required because microfluidic cell encapsulation is an inherently stochastic
process: for small numbers of cells, a wide range of cell numbers will be encapsulated in each
57
microtissue. In the best-case scenario, theory suggests that the distribution of cells within
microtissues will be determined by Poisson statistics 22 . However, due to issues of cell settling
and aggregation at high cell densities, the cell distribution will often be much more variable in
practice. Systems have been optimized to encapsulate single cells 230' 231, but controllably
encapsulating 10-100 cells, which are closer to the cell density used in spheroid culture2 20, is
more challenging. While working in this cell density regime, unavoidable variations in
microtissue density and composition of different cell types can reduce the statistical power of
the analysis. For example, if a microtissue population (n=500) immediately post-encapsulation
has a standard deviation that is 3x the mean fluorescence (a/p=3), one could measure a 40%
difference in proliferation with 80% statistical power. Since the population spread usually
increases over the course of the experiment due to biological variation, this power would
decrease even further for later time points. By contrast, using a pre-sort, initial spreads are
constrained to approximately a-/ =0.2, with final standard deviations between a/p=0.5 to 1. With
these sorted populations, even changes as small as 13% could be detected with 80% statistical
power. Further, we take advantage of the initial heterogeneity of the population to produce
multiple "bins" of encapsulated cell numbers from a single encapsulation step.
In the next phase, sorted microtissues are collected in tissue-culture wells for 2-6 days of
culture, during which they can be treated with soluble growth factors or drugs (Fig. 3.1d).
During this time, cells proliferate within the microtissues and can be visualized by microscopy.
At the desired time point, treated microtissues are collected and re-analyzed by large particle
cytometry for changes in overall fluorescence of the embedded cells (Fig. 3.1b). This method
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Figure 3.1. 3D tumor microenvironment screening platform. (A) Microfluidic droplet-based
encapsulation of tumor cells into microtissues that can be tuned with co-encapsulated stromal
cells or entrapped ECM molecules. (B) Produced microtissues are rapidly interrogated in
multiple fluorescent channels using large-particle flow analysis. (C) Cytometry-like flow sorting
separates and defines microtissues with controlled levels of homotypic and heterotypic
interactions. (D) Cellular microenvironment within microtissues is further modulated by
soluble factors such as cytokines or small molecule drugs. The extent of cell proliferation within
individual microtissues is then detected by flow analysis (B) to collect population-level data on
responses to microenvironmental conditions.
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(D) 3D culture and treatment-
offers higher throughput than methods that require serial imaging as a readout, and unlike
traditional bioassays that require release of cells from the microgels, our whole-microtissue flow
measurement is non-destructive. After every analysis step using our platform, each microtissue
population can be re-collected for additional culture periods and subsequent analysis, allowing
us to study the evolution of a single population over time.
3.3.2 Controlling tumor homotypic and heterotypic interactions
Cell-cell interactions, both homotypic and heterotypic, are among the most potent
modulators of cellular function. Our platform was designed to generate uniform populations of
microtissues of user-defined tumor cell (homotypic) and/or accompanying stromal cell
(heterotypic) densities. To demonstrate control over homotypic density, we generated a parent
population of microtissues, incorporating a range of numbers of murine non-small cell lung
cancer cells (393T5) bearing a constitutive fluorescent reporter protein (ZsGreen). The 393T5
NSCLC cell line was established from a primary tumor that formed distant metastases16.
Because total microtissue fluorescence, as measured using the COPAS, exhibits a linear
correlation with cell number (Fig. 3.2), we divided our parent population into multiple
subpopulations by enriching each bin for a particular range of encapsulated cells (Fig. 3.3a).
Examination of subpopulations immediately post-sorting reveals three distinctly separated,
narrow peaks (Fig. 3.3a). After three days in culture, cell growth within microtissues yields
populations that remained separable, demonstrating the ability to control homotypic density
over time (Fig. 3.3a). During these several days in 3D culture, tumor cells that were originally
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encapsulated as single cells (Fig. 3.3b) gave rise to tumor spheroids within the microtissues
(Fig. 3.3c), whereas the same cells typically grow as a monolayer when placed in 2D culture232.
Compared to spheroid models, which require several days to form 3D aggregates, multicellular
microtissues in our platform are formed with no time delay. Furthermore, the size and cellular
density of spheroids may vary over time due to proliferation and/or contractile forces. The
microtissues formed in this study display 3D growth features and allow control of volumetric
cell density and interstitial scaffold material.
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Figure 3.2. Correlation of number of (A) ZsGreen expressing 393T5 cells or (B) CellTracker
FarRed. DDAO-stained J2-3T3 fibroblasts encapsulated per microtissue as quantified by nuclear
staining and microscopy, with microtissue fluorescence in the corresponding channel as
detected by flow analysis.
In addition to the influence of homotypic interactions, stromal cells exert a significant
effect on tumor growth and the potential for metastasis 39 ,41'233. In order to study the impact of
these cellular interactions, previous studies have varied the stromal cell to parenchymal cell
composition within microgels, albeit at lower cell densities, by changing the flow rates of two
corresponding cell streams139. This "pre-encapsulation" control strategy yields desired
stromal:parenchymal cell compositions, at least on average, but the specific ratio in a given
61
microgel varies widely across the population. For example, if two cell types are mixed at a
density to give on average 8 cells per gel at a 1:1 ratio, Poisson statistics dictate that only 14% of
the resulting gels will actually have equal numbers of the two cells. For an average 1:3 stromal
to parenchymal ratio, even fewer gels will contain 1:3 cell numbers, with many gels containing
no stromal cells at allP 4. To exert finer stoichiometric control of tumor and stroma "post-
encapsulation", we incorporated stromal cells into our microtissue models by mixing and co-
encapsulating the 393T5 cells with J2-3T3 murine fibroblasts, and generated a parent population
of microtissues from one prepolymer mixture with a range of tumor to stroma ratios.
Subsequently, we performed a 2-parameter sort with green and far red fluorescence
representing the number of cancer cells and co-encapsulated fibroblasts, respectively (Fig. 3.3d).
We were able to separate the parent population into low (2.5±0.3 cells/gel) and high (5.0±1.7
cells/gel) numbers of fibroblasts, while holding the number of the cancer cells constant (7.0±2.7
cells/gel), thus generating distinct populations with a two-fold range of stromal to cancer ratios,
but consistent cancer cell density (Fig. 3.3e). By defining stromal composition "post-
encapsulation" rather than "pre-encapsulation," we take advantage of the stochasticity of
encapsulation to generate multiple populations with different ratios from a single microfluidic
process. This allows us to establish populations with a wide dynamic range of absolute cell
numbers as well as cellular composition patterns. Further, the tunability of the sorting
parameters (Fig. 3.4) allows user-defined tolerances to set the desired spread of cell ratios,
which will in general be tighter than those achieved using control over average cell
concentrations alone. Therefore, by controlling the bin thresholds, subsequent studies can be
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Figure 3.3. Control over homotypic and heterotypic microtissue composition. (A) Histograms
of ZsGreen-labeled 393T5 (lung cancer-derived cell line) microtissue populations, using sorted
ZsGreen fluorescence as a measure of homotypic density, before (Day 0) and after (Day 2)
proliferation. (B) Phase and epifluorescence images of 393T5 cells embedded within
microtissues at various cell densities and stained with CellTracker Green CMFDA. (C) Growth
of CellTracker CMFDA stained 393T5 cells within microtissues into spheroids over four days.
(D) Microtissues containing 393T5 cells co-encapsulated with CellTracker FarRed stained
fibroblasts, sorted by stromal cell density (Red fluorescence) while maintaining desired tumor
cell density (ZsGreen fluorescence) to achieve a two-fold change in stromal:tumor cell ratio
between the High vs. Low populations (E) Phase and epifluorescence images of 393T5 cells
(ZsGreen) co-encapsulated with J2-3T3 cells at different ratios. All scale bars: 50 tim.
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Figure 3.4. Flow analysis and sorting of microtissues containing co-encapsulated tumor
(393T5) and stromal (J2-3T3) cells. Individual microtissues (blue events) displaying variations
in number of each cell type. Y-axis = Green 393T5 cell density, X-axis = FarRed J2-3T3 cell
density. Low stromal ratio and high stromal ratio populations were defined by gating in both
channels, maintaining the same y-axis range in both gates, but shifting the x-axis gate to the left
(green events) for lower stromal density, and to the right (red events) for higher stromal
density.
3.3.3 Modulating cell proliferation with microenvironmental factors
At the molecular level, ECM and soluble factors play a large role in modulating cellular
function. In cancer, VEGF secretion stimulates angiogenesis, which is a critical component of
tumor growth2 34. Similarly, matrix remodeling is correlated with a more invasive phenotype'
235. We were interested in the ability to test how cytokines and ECM modulate metastatic
potential in a 3D context, using proliferation as a surrogate for invasive growth. The
composition of our PEG-DA hydrogels (10 wt%, 20kDa) was chosen to form a semi-permeable
network (7 nm mesh size236) that allows diffusion of soluble proteins with sizes up to 100 kDa 237,
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which includes most cytokines. First, we encapsulated 393T5 cells in microtissues, and we
sorted them to enrich for a particular homotypic density (17.4±3.4 cells/gel), which we held
constant across experiments. Then we cultured the enriched microtissue population for two
days in media supplemented with growth factors that have been widely implicated in cancer
progression: 50 ng/ml of EGF, HGF, VEGF, or TGF-P (Fig. 3.5A). Exposure to EGF, HGF, and
VEGF had no significant effect on proliferation as compared to vehicle control-treated
microtissues. The lack of impact of EGF is consistent with the fact that these cells overexpress
Kras, which is downstream of the EGF receptor1 6 234. Interestingly, treatment with TGF-p led to a
significant reduction in proliferation (p < 1010). TGF-p is known to have a tumor suppressor
effect in some early-stage cancers but has also been shown in other cases to promote metastasis,
leading to epithelial to mesenchymal transition, especially in later stage cancers 238. While the
393T5 cell line was derived from a primary tumor with proven metastatic potential, our data
suggests that the primary tumor still displays an early-stage phenotype that can be suppressed
by TGF-P, consistent with observations of other primary lung cancer models 23 9.
In addition to examining the impact of soluble factors, we also applied our platform to
study the effect of ECM proteins on metastatic potential in 3D. ECM interactions with cell
integrins are known to not only trigger direct downstream signaling, but also to modulate the
response of cells to other inputs such as drugs and growth factors through pathway crosstalk240'
241. To include ECM in our microtissues, we co-encapsulated 393T5 cells with collagen I (300
kDa), laminin (850 kDa), or fibronectin (440 kDa), adding 20 Pg/ml of the protein to the pre-
polymer mixture so that it is physically incorporated within microtissues during
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Figure 3.5. Modulation of tumor cell proliferation by cytokines and ECM. 393T5 growth
within microtissues (initial 17.4+/-3.4 cells/gel) when (A) cultured in media containing 50 jag/ml
VEGF, HGF, EGF, or TGF-P, or (B) encapsulated in the presence of to 20 Vg/ml of laminin,
fibronectin, or collagen-1 that remain physically entrapped within the hydrogel scaffold.
Average number of cells per gel calculated from microtissue fluorescence using linear
regression. * indicates p < 0.01.
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photopolymerization. Due to the size of the hydrogel network, large proteins (>150 kDa) are
able to diffuse only very slowly through the gel (Fig. 3.6). Therefore, we expect that the even
larger ECM proteins remain effectively entrapped in the microtissues over the timescale of our
experiments. Also, at this low concentration, the ECM proteins are unlikely to significantly
impact the physical properties of the 100 mg/ml PEG-DA hydrogel. Thus, baseline nutrient
diffusion and cell growth rates are comparable, allowing a horizontal comparison of ECM
molecule signaling effects in 3D using minimal amounts of expensive ECM materials, and
without the confounding factor of varying mechanics (e.g. collagen gels vs. fibrin gels) or
network properties. ECM-functionalized microtissues enriched for a specific homotypic density
were sorted and cultured for 2 days (Fig. 3.5b). Consistent with their pro-metastatic phenotype,
the tumor-derived cells exhibited significantly elevated proliferation in the presence of
fibronectin (p < 10-10), which has been shown previously to correlate with metastatic activity 24 2,
24. In contrast, growth was inhibited in the presence of both laminin (p < 0.01) and collagen I (p
< 10-4), again demonstrating a tumor cell preference for proliferation in an invasive-supporting
matrix over basement membrane proteins. Additionally, collagen I has been reported to induce
TGF-P3 expression in some lung cancer cells 244, which could lead to an indirect growth
inhibition mediated by this ECM, consistent with our observations in response to TGF-p3
exposure, described above (Fig. 3.5a).
67
Figure 3.6. Epifluorescence microscopy of cell-free microtissues containing encapsulated
proteins. Microtissues are formed from either (A) prepolymer containing 20 [ig/ml of Texas Red
labeled antibody (rabbit, polyclonal IgG), or (B) control blank PEG prepolymer. Microtissues
were washed in PBS for 24 hours post-polymerization. Scale bar = 100 pm.
3.3.4 Microenvironmental modulation of tumor drug response
Having demonstrated that our sortable microtissue platform can be used to assess the
responsiveness of tumor cell populations to soluble as well as embedded matrix proteins, we
sought to apply this system to conduct a small-scale pilot drug screen. In contrast to
conventional 3D gels, miniaturized tumor microtissues offer the advantage for screening
purposes in that reagent costs can be reduced, especially with respect to the amount of drug
needed to treat a certain media volume, while the number of replicates is maximized.
Combined with its high-throughput readout that will reduce experimental time and effort
needed per drug, our platform offers extreme scalability to support even broader screens. As a
first proof of concept, we hypothesized that this platform could be used to probe candidate
drugs that impact tumor cell proliferation specifically in a 3D architecture, as opposed to any
outcomes observed in conventional 2D culture conditions. Given that exogenously supplied
TGF-p inhibited 393T5 proliferation (Fig. 3.5a), and perturbations in TGF-s signaling have been
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found to be strongly tumor- and context-dependent 238, we selected several small-molecule
inhibitors that disrupt aspects of the TGF-p signaling pathway: SB525334 (TGFpR1), SJN 2511
(TGFpR1), and LY2157299 (TGFpR2, TGFPR1). Dorsomorphin (AMPK, ALK2, ALK3, ALK6),
DMH-1 (ALK2), and GW5074 (c-raf) were also tested and all treatments were compared to the
growth of DMSO vehicle-treated microtissues, or TGF-p as a negative control for 3D growth.
For 3D assays, encapsulated 393T5 cells were sorted for a specific population density and
cultured for several days in the presence of 10 iM of the inhibitors. Proliferation was assayed
based on the change in microtissue fluorescence over time. We compared these results to those
found in a 2D assay, where 393T5 cells were seeded on tissue culture microplates and
proliferation was tracked by microplate well fluorescence2 19.
Using this assay, we detected statistically significant alterations in microtissue
proliferation in response to several of the drug candidates, relative to untreated and DMSO
controls (Fig. 3.7a). The TGFpR1 inhibitor, SB525334, was one of several compounds that
exerted similar effects in both 3D and 2D conditions, in that it led to reduced proliferation in
each case (Fig. 3.7b). Dorsomorphin caused cell death in both geometries, and GW5074 elicited
little to no anti-proliferative effect (Fig. 3.7a,b). However, we noted marked differences between
2D and 3D responses to TGF-p and LY2157299. Specifically, while TGF-p inhibited proliferation
in 3D as observed previously, the cytokine did not exert any significant effect in 2D. The
opposite trend was observed in response to the TGFpR1/TGFPR2 inhibitor, LY2157299, in that it
inhibited proliferation in 2D cultures, but did not alter 3D microtissue growth (Fig. 3.7a, b). We
extended our observations by repeating the drug screen using a second cell line isolated from a
mouse with the same genetic background (394T4). Consistent results were obtained when the
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Figure 3.7. Comparison of 393T5 (A-B) and 394T4 (C-D) lung cancer cell response to drugs
when cultured in 3D microtissues (AC) vs. in 2D monolayers (B,D). Cells were treated in
both formats with 10 iM of SB525334 (TGFPR1), SJN 2511 (TGFpR1), LY2157299 (TGFpR2,
TGFpR1), Dorsomorphin (AMPK, ALK2, ALK3, ALK6), DMH-1 (ALK2), or GW5074 (c-raf), or
50 ng/ml of TGF-p. Microtissue or tissue-culture well fluorescence for each condition are shown
after 3 days of culture for 393T5 cells and 5 days of culture for 394T4 cells, which proliferate
slower in control conditions, so that the two cell lines undergo the same number of population
doublings during each assay. Initial conditions are labeled in green (3D: 13.5 +- 2.5 cells/gel, 2D:
26x10 3 cells/cm 2 ). Gray rectangles indicate the range of p=0.05 significance by ANOVA with
Tukey post-hoc test compared to DMSO controls. Red conditions had significantly reduced cell
numbers compared to DMSO controls, whereas blue conditions had significantly increased
proliferation rates.
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growth responses of drug-treated, sorted microtissues bearing 394T4 cells were compared to 2D
cultures (Fig. 3.7c, d). LY2157299 is a clinically relevant compound undergoing trials for use in a
variety of cancer patients 24 -2 47, and has been reported to bind to both receptors, but to TGFpR2
with greater specificity (IC50 2 nM vs. 86 nM for TGFPR1) 2 4 1. Canonically, TGF-p binds to
TGFpR2, which then recruits and phosphorylates TGFpR1. However, it is known that specific
TGF-p receptors regulate different activities induced by TGF-p, possibly due to the recruitment
of alternative signaling complexes 249. Specifically, several published accounts point to TGFpR2
primarily regulating DNA synthesis, whereas TGFpR1 has been suggested to have a greater
impact in mediating matrix synthesis or degradation 250 -25 2. This distribution of functions could
be one explanation for why only LY2157299 (inhibiting TGFpR2 for DNA synthesis in addition
to TGFpR1) would exhibit the context-dependent but opposing effects on proliferation
compared to direct TGF-p treatment, whereas the TGFpR1-only inhibitors (SB525334, SJN2511)
did not.
Given the vast, and often contradictory, published literature regarding the roles of TGF-
p and its receptors, particularly in cancer biology, the impact of drugs may be highly contextual
and dependent on tumor models, culture conditions or architectures. This pattern is particularly
well-illustrated in our current results and also serves to emphasize the value and importance of
evaluating drug candidates in multiple in vitro model systems - perhaps in parallel with
established therapeutics in order to calibrate the specific assay readout. In this case, the
observation that a TGF-p receptor inhibitor exerts opposing effects on tumor cell proliferation
when compared with responses to its ligand is perhaps not unexpected. However, the fact that
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this same pattern is consistently reversed in our 2D in vitro architecture raises important caveats
with respect to the potential responsiveness of tumor cells when this pathway is manipulated in
vivo in a clinical setting. Notably, a finding consistent with our result was observed by another
group examining a mouse model of metastatic breast cancer 233. In their system, activated
TGFsR1 delayed primary tumor growth and accelerated formation of lung metastases, whereas
addition of dominant-negative TGFsR2 had the opposite effect. The authors speculate that TGF-
s functions as a tumor suppressor in a primary lesion, but promotes metastasis dissemination,
which is consistent with our findings that primary-tumor derived lung cancer cells remain
responsive to TGF-s stimulation.
3.4 Conclusion
We have demonstrated a platform that integrates microfluidic droplet encapsulation to
produce microscale tunable microenvironments with a high speed analytical system based on
in-flow sorting and analysis of microtissues. This platform utilizes tissue engineering materials
and methods as well as microfluidic technology, but obviates common problems with 3D tissue
engineering constructs, such as laborious fabrication, low-throughput imaging analysis, and
low statistical power. The capacity for high-speed analysis enables the detection of hundreds to
thousands of individual events in order to assay the impact of microenvironmental conditions
on proliferation. Moreover, by sort-based enrichment of defined microtissue populations to
limit variability in cell number and/or composition, our platform reduces noise while increasing
replicates, which offers the potential to achieve strong statistical significance in biological
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studies. We used this platform to explore the impact of TGF-p signaling on non-small cell lung
cancer proliferation. We demonstrated microenvironmentally-mediated modulation of tumor
cell proliferation in this platform and we observed context-dependent signaling via the TGF-p
pathway in our model cell line. Modification of the microtissue scaffold with collagen-1, or
treatment of microtissues with TGF-p, diminished cancer cell proliferation uniquely in the 3D
setting. Furthermore, a TGFpR1/TGFPR2 inhibitor (LY2157299), but not TGFpR1-only
inhibitors, decreased proliferation in 2D yet promoted growth in a 3D context. Based on these
results, we predict that the anti-proliferative influence of TGF-p observed in 3D may be
mediated by TGFpR2. An interesting extension of these findings would be to conduct a related
in vivo preclinical experiment by treating the tumor-prone genetic mouse model"6 , which gave
rise to our 393T5 and 394T4 lines, with oral LY2157299. Based on our findings, one might
predict that the drug might limit or at least delay the appearance of distant metastases, but may
not impact the development of primary lung tumors. Future work involving the combined
flow-enrichment of subpopulations of microtissues will apply our platform to explore
combinations of microenvironmental conditions, such as drug responsiveness in the presence of
particular ECM combinations or ratios of heterotypic stromal cell contacts. To support an
expanded screen of cues, a microfluidic combinatorial mixer could be incorporated upstream of
droplet encapsulation so that ECM and stromal composition could be controlled on-chip. Also,
new encapsulation devices including multiple parallel droplet nozzles could augment the
microtissue fabrication rate for a full-scale drug screen. Further utility of this platform may be
found in extension to other tissues and disease contexts including stem cell or other
73
developmental biology settings, in which the influence of microenvironmental signals has been
challenging to study in a methodical, manipulable and screen-compatible fashion.
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Chapter 4: Hepatocyte Microtissues for Toxicity Screening
and Drug-drug Interactions
4.1 Introduction
Unpredicted liver toxicity is a major cause of drug development failures and post-
market withdrawals." Animal models often fail to fully reflect the complexities of human liver
behavior due to cross-species differences in hepatocyte function, underscoring the need for
human-specific pre-clinical models. Current in vitro models such as liver slices and microsomes
are not amenable to long-term studies of intact cell behavior, while cell lines do not reflect the
full phenotype of primary hepatocytes. Thus, primary hepatocytes are ideal candiates for drug
development applications but undergo a rapid loss of differentiated function and viability once
ex vivo.27, 28 This has led to various approaches to stabilize hepatocyte function by recreating
microenvironmental factors typically found in native liver, such as cell-cell interactions (both
homotypic24 and hetereotypic56-60 ), cell-matrix interactions, 48 , 254 and tissue architecture' 05. In
many cases it was found that hepatocyte phenotype and function were influenced by culture in
a 3D rather than 2D system, for example when cultured as spheroids, 46 , 255-259 sandwich gels, 4 9-12
porous scaffolds, 71-73 or encapsulation in in naturals3-15 , 106 or synthetic hydrogels.75, 114, 115
Hepatocytes cultured in 3D may be more representative of in vivo behavior, but many of these
strategies were developed for cell-based regenerative therapies, in which the major challenge is
scale-up of tissue size.
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Miniaturization of cell-laden hydrogels into <250 jam units, called "microtissues," is a
promising new approach to tissue engineering that provides several distinct advantages over
both scaffold-free 3D culture (i.e.. spheroids) and conventional hydrogels. The cell-
encapsulating hydrogel serves a shear-protective function during perfusion, spinner culture, or
general handling.20 -2 2 It also prevents aggregation even during culture in small volumes so that
remaining transport of oxygen and nutrients is not limiting.20 ,263 Further, functionalization of
the scaffold enables controlled addition of exogeneous factors to tune the microenvironment,
such as such as entangled whole ECM proteins,12 ,264 adhesive peptides, 114,116,123 or tethered cell
signling factors. 132-134 Due to the miniaturized format, microtissues are amenable to
multiplexed 149 and high-throughput flow analysis, 264 bypassing more time-consuming readouts
such as confocal microscopy 12 Finally, there has been extensive interest in using microtissues
as building blocks for bottom-up assembly of patterned tissues 1 4, 172 ,2 25 and packed-reactor-like
devices.148' 194, 199 However, these studies have thus far used only the more robust and readily
cultured hepatocellular carcinoma-based cell lines, and have yet to be extended to primary
hepatocytes.
In this chapter, we report the fabrication of microtissues comprised of primary
mammalian hepatocytes that can be mass-produced for drug screening applications. To
stabilize hepatocyte function post-isolation, we first developed a method to form small (<10-
cell) aggregates, called "pucks," by patterning hepatocytes on collagen microislands and then
detaching the confluent islands. These micropatterned cell-cell interactions enabled survival
hepatocyte survival in bulk PEG hydrogel as well as in 100 jam microtissues, which were
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produced in mass by continuous microfluidic droplet-based cell encapsulation. Hepatic
microtissues exhibited intact hepatocellular activity as characterized by albumin production
and species-specific induction of drug metabolism enzymes. Finally, leveraging the dynamic
gene expression and intact cellular machinery of primary hepatocytes, we demonstrate for the
first time that hepatic microtissues can be used to predict hepatotoxicity and known drug-drug
interactions.
4.2 Materials and Methods
Plate patterning
Topographically patterned polydimethylsiloxane (PDMS, Dow Corning) masking molds
that defined collagen microislands were cast from silicon masters. Standard photolithographic
methods were used to fabricate the masters with 50 pm tall raised circular pillars of SU-8 2050
photoresist (Microchem, MA). Intermediate PDMS "negatives" were cast from the master and
coated with (tridecafluoro-1,1,2,2-tetrahydrooctyl)-1-trichlorosilane (UCT Specialties) for 1 hour
in a vacuum desiccator. Final PDMS masking molds were then cast from the negatives to again
have raised pillars, and cut into appropriate discs to fit into 6-well plates.
Ultra-Low attachment plates six well plates (Corning) were coated with 0.15 mg/ml
Type I collagen (rat tail, BD Biosciences) at 370 C for 1 hour. Wells were rinsed with deionized
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water and dried with nitrogen. PDMS masking molds were carefully placed into each well,
using gentle pressure to ensure that all parts of the pattern adhered to the well, and the entire
plate was subjected to air plasma treatment (SPI Supplies) for 15 seconds. Non-patterned
control plates meant to have a homogenous collagen surface coating did not undergo this last
step. Masking molds were removed from wells for reuse, and plates were sterilized by 15
minutes of UV exposure prior to use.
Cell culture and puck formation
Hepatocytes were isolated from 2- to 3-month-old adult female Lewis rats as previously
described.49, 265 Hepatocyte culture medium consisted of Dulbecco's Modified Eagle Medium
(DMEM, Invitrogen) with 10% fetal bovine serum (Invitrogen), 0.5 U/ml insulin (Lilly), 7 ng/ml
glucagon (Bedford Laboratories), 7.5 tg/ml hydrocortisone (Sigma), 10 U/ml penicillin
(Invitrogen), and 10 mg/ml streptomycin (Invitrogen). J2-3T3 fibroblasts were cultured in
DMEM with 10% bovine serum (Invitrogen), 10 U/ml penicillin, and 10 mg/ml streptomycin.
mCherry J2-3T3 fibroblasts were generated by ViroMag R/L (Oz Biosciences) mediated
transduction of lentivirus containing mCherry under control of the EFlalpha promoter
(Promega). Transduced mCherry fibroblasts were subsequently selected by puromycin
followed by fluorescence-activated cell sorting. All cells were cultured in a 5% CO2 humidified
incubator at 370 C.
To seed freshly isolated hepatocytes, cells were first pelleted at 50xg for 5 minutes and
resuspended in hepatocyte medium without serum at a cell density of 2x10 6 hepatocytes/ml.
One ml of this suspension was added to each well of a patterned or non-patterned 6-well plate.
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Hepatocytes were allowed to attach for 2 hours to any adhesive regions of the plate in the
incubator, with gentle linear shaking every 15 minutes to re-disperse unattached cells. Progress
of seeding was monitored under a microscope. After microislands were seeded to confluence,
each well was rinsed twice with 2 ml of medium to remove any remaining unattached cells. Cell
number on each island was manually counted three hours after initial plating,when cells were
firmly attached but individual cell borders could be easily distinguished. For hepatocyte-only
pucks, the seeded cells were then cultured in 1 ml of full hepatocyte medium with serum
overnight. To form pucks that contain both hepatocytes and fibroblasts, J2-3T3 cells were then
added to each well (0.5x106 cells in 1 ml hepatocyte medium) and allowed to seed overnight,
with gentle shaking every 15 minutes for the first 2 hours.
Encapsulation in bulk PEG gels
Hepatocytes that had been cultured on patterned or non-patterned 2D plates for 24
hours were detached using 2 mg/ml collagenase (Type IV, Invitrogen) in DMEM. Within 5
minutes, multicellular pucks lifted from the plate but did not dissociate into single cells. Pucks
or unpatterned cells were diluted in hepatocyte medium, pelleted (50xg, 5 min), and then
resuspended at an effective cell density, calculated from the number of microislands per well
and the number of cells per island, of 8x106 cells/ml in PEG prepolymer. The prepolymer
solution consisted of 100 mg/ml PEG-diacrylate (20 kDa, Laysan Bio) in heavy DMEM (DMEM
adjusted to have a specific gravity of 1.06 by OptiPrep density medium, Sigma) with 1:100 v/v
photoinitiator working solution (100 mg/ml Irgacure 2959, Ciba, in n-vinyl pyrrolidone, Sigma).
The adhesive peptide RGDS was incorporated by also including 10 mM of Acrylate-
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PEG(3.4kDa)-RGDS monomers that were prepared as previously described 4 in the
prepolymer. For co-encapsulation of fibroblasts with hepatocyte pucks, J2-3T3 fibroblasts were
detached with 0.25% Trypsin-EDTA (Invitrogen), pelleted, and also resuspended in prepolymer
for a final 1:1 ratio of fibroblasts and hepatocytes (8x10 6 fibroblasts and 8x106 hepatocytes per
ml).
Disc-shaped, or "bulk" PEG gels were fabricated using hydrogel polymerization
apparatus described previously.11 3 Briefly, prepolymer solution containing cells was loaded into
a 8.5 mm diameter, 250 jam thick silicone spacer, sandwiched between a Teflon base and a glass
cover slip, and polymerized by exposure to UV light from a spot curing system with a
collimating lens (320-390 nm, 21 mW/cm 2, 12 s; Lumen Dynamics). Each gel was soaked in rinse
media for 1 hour to remove any un-polymerized components and was subsequently cultured in
0.5 ml of hepatocyte medium. All experiments were performed with quadruplicate gels for each
condition.
Microfluidic encapsulation in microtissues
Droplet-based microfluidic encapsulation devices were fabricated as previously
described. 22 For microfluidic encapsulation, hepatocyte-only or hepatocyte-fibroblast pucks
were lifted using 2 mg/ml collagenase, pelleted (50xg, 5 min), and then resuspended at an
effective hepatocyte density of 30x10 6 cells/ml in PEG prepolymer. The cell suspension was
loaded into a syringe and injected into the device at 200 l/hr. Simultaneously, fluorocarbon oil
(Fomblin Y-LVAC, Solvay Solexis) containing 0.5 w/v% Krytox 157 FSH surfactant (DuPont)
was also injected into the device as an oil phase. At a droplet-generating nozzle, the aqueous
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cell suspension was broken into 100 pm-diameter droplets of cells and prepolymer in oil, which
were then continuously polymerized on chip by exposure to UV light (320-390 nm, 500
mW/cm 2, 0.5 s; Lumen Dynamics) before exiting the device. Microtissues collected from the
device were separated from oil and washed on a 70 Vm strainer to remove any un-polymerized
components. To remove gels that did not contain any cells (due to settling of the pucks during
injection), microtissues were centrifuged at 50xg for 5 minutes in a Percoll (Sigma) density
medium solution (12.5 1I isotonic 1.12 g/ml density Percoll stock per ml of media). Pelleted
microtissues were resuspended in hepatocyte medium and cultured in 40 jam strainer caps (BD
Falcon) as inserts for 24-well plates. All experiments were performed with quadruplicate wells
for each condition.
Biochemical assays
Supernatant was collected every other day from bulk gels or microtissues. Secreted
albumin in the supernatant was quantified by an enzyme-linked immunosorbent assay (ELISA)
kit using sheep anti-rat albumin antibodies (Bethyl Labs) and horseradish peroxidase detection
(3,3',5,5'-tetramethylbenzidine, Invitrogen).
For enzyme induction experiments, microtissues were pre-treated with inducers for 72
hours beginning at 48 hours post-encapsulation. Stock solutions of inducers were prepared in
dimethyl sulfoxide (DMSO) and diluted 1:1000 for final concentrations of 50 jM omeprazole
(Sigma), 25 jM rifampin (Sigma), and 10 jM dexamethasone (Sigma). Phenobarbital (Sigma)
was dissolved at 40 mM in deionized water and diluted to a final concentration of 200 jM.
Vehicle controls were pre-treated with 72 hours of either 1:1000 DMSO or 1:200 water.
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Cytochrome P450 activity was assessed with luminogenic P450-Glo kits (Promega) according to
vendor instructions for non-lytic assays using cultured cells. Microtissues were incubated with
Luciferin-PFBE (1:40 dilution in phenol-free DMEM), Luciferin-CEE (Cyp1A1, 1:66 dilution), or
Luciferin-H (Cyp2C9, 1:50 dilution) for 3 hours. Processed medium samples from each strainer
of microtissues were collected and luciferin metabolites measured on a luminometer (Berthold,
10 s).
Acetaminophen treatment
For hepatotoxicity experiments, microtissues were cultured for 72 hours post-
encapsulation and then exposed to 0 - 40 mM of acetaminophen (Sigma) for 24 hours. All
samples contained a final 0.8% v/v DMSO. For drug interaction experiments, microtissues were
cultured for 48 hours post-encapsulation, exposed to various inducers or controls for 72 hours,
and then dosed with 40 mM of acetaminophen in the presence of inducers for 24 hours.
Large-particle flow cytometry
High throughput analysis of microtissue viability was performed by first staining
microtissues in suspension with the live-dead fluorescent stains calcein AM (5 tg/ml) and
ethidium homodimer (2.5 jg/ml) for 15 minutes at 370C. Whole-microtissue levels of
fluorescence were detected using a BioSort large particle flow cytometry (Union Biometrica)
equipped with a 488 nm excitation laser. Microtissues were gated for on the basis of Time of
Flight (size) and Extinction (optical density) to exclude debris. Fluorescent signal acquisition
parameters were set as follows: Gains - Green 3, Red 3, PMT control - Green 300, Red 700.
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Compensation was applied to subtract 90% of the green signal from red. Scatter plots were
created using BioSorter software. Raw data was also exported for processing with custom
MATLAB code.
Immunohistochemistry, live-dead staining, and imaging
For immunohistochemistry, fresh isolated hepatocytes or hepatocyte microtissues were
fixed in methanol and 10% acetic acid and then gently pelleted in eppendorf tubes. Cell pellets
were resuspended in histogel (Thermo Scientific), repelleted, and placed on ice for histogel
gelation. Histogel-encapsulated cell pellets were processed, embedded, and sectioned. Sections
were incubated with primary antibodies against either pan-cytokeratin (1:800, Sigma) or
arginase-1 (1:400, Sigma) and then with species-appropriate secondary antibodies conjugated to
Alexa 488 or 555. Images were obtained using a Nikon Ti scanning-confocal microscope.
Cell viability within bulk gels and microtissues was examined using calcein AM (5 jig/ml) and
ethidium homodimer (2.5 pg/ml) fluorescent stains (Molecular Probes, incubated with cells for
15 minutes at 37'C) to stain live and dead cells respectively. Images were acquired using a
Nikon Ellipse TE200 inverted fluorescence microscope and CoolSnap-HQ Digital CCD Camera.
MetaMorph Image Analysis Software was used to uniformly adjust brightness/contrast,
pseudocolor, and merge images.
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4.3 Results
4.3.1 Control and uniformity of hepatocyte patterning
Collagen micro-islands were defined on tissue culture plates using a soft lithography
process59 wherein a layer of adsorbed collagen is first masked by contact with a PDMS mold
(Fig. 4.1a). Protruding PDMS posts of various sizes (50, 75, and 100 pm diameters) (Fig. 4.1b, i-
iii) were used to protect collagen in contacted regions from plasma ablation, resulting in 50-100
iam circles of remaining collagen. This range of island sizes was selected to be compatible with
targeted 100 pm diameter microtissues and the 70 pm droplet-generating nozzle during
microfluidic encapsulation.
Freshly isolated rat hepatocytes seeded onto micropatterned collagen islands of various
sizes (50, 75, and 100 pm diameters). Hepatocytes densely covered and adhered only to the
areas of collagen microislands (Fig. 4.1b, iv-vi). This patterning and process was robust and
scalable to large areas (Fig. 4.2), which enabled mass production of patterned hepatic islands.
After one day of culture, (Fig. 4.1b, vii-ix), hepatocytes spread to form a confluent 2D layer over
each microisland. When treated with collagenase to digest underlying collagen, hepatocyte
islands, or "pucks," detached from the plate as cohesive units (Fig. 4.1b, x-xii) without
dissociating into single cells, presumably due to minimal digestion of cell surface proteins by
collagenase. Cell number in each puck was directly related to island area and generally
followed the Poisson distribution (Fig. 4.1b, xiii-x; 5.6±1.7 cells for 50 iam islands, 7.9±2.0 cells
for 75 pm islands, and 11.8±2.4 cells for 100 pm islands). All subsequent studies used pucks
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Figure 4.1. Hepatocyte puck formation and detachment from patterned collagen
microislands. A) Schematic illustrating the definition of adhesive collagen islands on plastic,
hepatocyte seeding and spreading over 24 hours, and detachment with collagenase. B) Phase
images showing i-iii) PDMS molds to define island size, iv-vi) primary rat hepatocytes initially
seeded on the islands, vii-ix) confluent hepatocyte islands after 24 hours of culture, and x-xii)
detached pucks. All scale bars are 200 pm. xii-xv) Histogram of number of the hepatocytes in
each size of puck.
85
A B
|
Area shown: 13.7 mm2
C),
Figure 4.2. Microisland seeding (A-C) and puck formation (D-F) by primary hepatocytes over
large areas. All scale bars = 200 tm.
formed by 50 pm islands, which resulted in multicellular pucks (smaller island sizes resulted in
many islands only capturing single cells) that remained small enough for facile microfluidic
handling. After removal from collagen substrate, hepatocytes in freely floating pucks expressed
both cytokeratin and arginase-1 (Fig. 4.3), indicating that puck culture enabled selection for
viable hepatocytes after fresh isolation procedures. Taken together, these results show that
micropatterning to prompt the formation of cell-cell contacts was facile and effective.
4.3.2 Effect of homotypic contacts on 3D albumin secretion
To examine whether pre-clustering of hepatocytes improved hepatic function after
encapsulation in a 3D hydrogel, we first tested the albumin secretion of the cells within
monolithic, "bulk" PEG gels as a first measure of health and viability. For the hydrogel scaffold
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Figure 4.3. Hepatocyte pucks express liver proteins. After removal from collagen substrate,
hepatocytes in freely floating pucks expressed both cytokeratin (red) and arginase-1 (green).
Expression levels were greater in pucks (right) compared to freshly isolated purified
hepatocytes (left), indicating that puck culture selected for viable hepatocytes after isolation
procedures.
material, 10 wt% PEG-DA (20k) was chosen because it is 1) loose enough to allow diffusion of
oxygen/nutrients/proteins to and from the cells,2042) biologically/immunologically inert, and 3)
can be functionalized with acrylate-containing ligands.111, 131, 135, 136, 266 As a control condition,
hepatocytes were randomly seeded in collagen-coated but unpatterned 6-well plates at 600,000
cells/well, which was chosen from the theoretical number of cells that would seed in a 50 tm-
island patterned well assuming 5.6 hepatocytes per island. At this density, cells on the
unpatterned surfaces are able to make chance cell contacts as they seed in 2D and form loose
cords of cells when detached (Fig. 4.4).Hepatocytes were randomly seeded ("unpatterned") or
micropatterned using collagen islands for 24 hours, lifted by collagenase, resuspended in
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B Randomly seeded
Figure 4.4. 2D culture of hepatocytes on either (A) micropatterned islands, or (B) unpatterned,
collagen-coated plastic. All scale bars = 200 am.
hydrogel prepolymer, and photopolymerized into 14 ul disc-shaped gels (Fig. 4.5a). Live/dead
staining with calcein AM and ethidium homodimer on the encapsulated pucks indicated >80%
viability after 3 hours (which is comparable to the ~80% viability of lifted pucks, indicating that
the polymerization process was not additively cytotoxic (Fig. 4.5b). Hydrogels containing
hepatocyte pucks exhibited increasing albumin secretion during the first week after
encapsulation followed by sustained secretion for up to two weeks. Albumin secretion in
hydrogels containing pucks was over 3-fold greater compared to control hydrogels containing
unpatterned hepatocytes at 8 days (p = 0.0571, n = 4, Wilcoxon rank sum test). These results
demonstrate that micropatterning hepatocytes to form hepatic 'pucks' prior to encapsulation
improve hepatocyte phenotype after encapsulation in a 3D hydrogel.
4.3.3 Effect of other supporting factors in 3D albumin secretion
Co-culture of hepatocytes with a second cell type,58' 59 or the presence of adhesion
proteins or peptides such as RGDS, 75 14 have been reported previously to support the
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Figure 4.5. Hepatocyte pucks in 8.5mm-diameter bulk PEG hydrogels. A) Hepatocytes were
detached from either patterned or random 2D culture after 24 hours and encapsulated in a 3D
PEG scaffold. B) Live-dead stain of hepatocyte pucks within PEG hydrogel. C) Albumin
secreted into the supernatant from hepatocyte-laden gels (n = 4). D) J2-3T3 fibroblasts were co-
encapsulated along with hepatocytes into the hydrogel, which was modified by RGDS adhesive
peptides. E) Epifluorescence image of hepatocyte pucks (green, calcein) and fibroblasts (blue,
mCherry) co-culture within a gel. F) Albumin secreted into the supernatant from gels
containing hepatocyte pucks with additional fibroblasts and/or RGDS (n = 4). Error bars show
standard error (SEM). All scale bars are 200 tm.
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maintenance of primary hepatocyte function. Thus, we explored the incorporation of both
heterotypic cell-cell interactions and extracellular matrix-derived adhesive moieties into the 3D
gels (Fig. 4.5d). To achieve the former, a single-cell suspension of J2-3T3 fibroblasts expressing
mCherry was mixed into the prepolymer used to encapsulate hepatocyte pucks. Resultant gels
(Fig. 4.5e, shown in blue) contained J2-3T3 fibroblasts distributed throughout the volume of the
gel, at length scales (<100 tm from the nearest hepatocyte) that previous studies have
demonstrated to enable paracrine signaling through soluble factors146 as well as, in some cases,
immediately adjacent to hepatocytes. Adhesive moieties were incorporated into gels by
chemically conjugating acrylate-functionalized RGDS peptides (10 mM) into the hydrogel
network. 3D co-culture of fibroblasts with hepatocyte pucks resulted in a greater than 2-fold
increase of albumin production relative to hepatocyte-only controls in the first week (Fig. 4.5f).
More importantly, the maintenance of albumin production over time was extended in the
presence of fibroblasts from 20 days to over 7 weeks. Conversely, adhesive peptides did not
significantly affect albumin production curves in RGDS-containing gels compared to non-
adhesive controls, whether the gels contained hepatocyte pucks only or hepatocyte pucks with
fibroblasts (Fig. 4.5f). Together, these results demonstrate that supportive cues from J2-3T3
fibroblasts but not RGDS adhesive peptides are crucial for long-term hepatocyte survival in this
system.
4.3.4 Microfluidic production of hepatic microtissues
Having verified that hepatocyte pucks retain function when encapsulated with
fibroblasts in macroscopic bulk PEG hydrogel, we sought to miniaturize the 3D engineered
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tissue into 100 ram-diameter "microtissues." For these studies, we produced individual droplets
of prepolymer containing cells and then polymerized these cellular droplets to form
"microtissue" hydrogels on-chip (Fig. 4.6a). Hepatocyte pucks, fibroblasts, and
photopolymerizable prepolymer were mixed to form a combined aqueous stream that was
injected into the encapsulation device. This aqueous stream was designed to intersect with an
oil stream of oxygen-permeable fluorocarbon oil at a droplet-generating nozzle, such that
prepolymer-in-oil droplets were continuously produced. Droplets were subsequently
polymerized within the device (Fig. 4.7). Polymerized, spherical microtissues containing
multicellular pucks were collected from the outlet of the chip. Viability of microtissues as
assessed by live-dead staining was similar to that of bulk-encapsulated pucks (Fig. 4.6b).
Similar to bulk hydrogel studies, the presence of dispersed fibroblasts mixed into the gels
significantly increased total albumin produced over 16 days (Fig. 4.6c).
Because fibroblasts were found to play such a key supportive role in maintaining
hepatocyte puck function, we explored the option provide this heterotypic interaction earlier in
the process, during the first 24 hours post-hepatocyte isolation. To include fibroblasts when
hepatocytes are stabilizing in 2D, fibroblasts were seeded onto any remaining space on the
microislands after hepatocytes had been allowed to attach for 2 hours. When unattached
fibroblasts after 2 more hours are rinsed off, 95% of the resulting islands contained both cell
types (Fig. 4.8), and as before, formed confluent circles of cells over 24 hours that could be
discretely detached by collagenase to produce mixed hepatocyte-fibroblast pucks. Microtissues
containing hepatocyte-fibroblast pucks, where the two cell types were brought into contact on
the day of hepatocyte isolation, will be hereafter referred to as "hepatic microtissues" and
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Figure 4.6. Microfluidic encapsulation of hepatocyte pucks. A) A mixture of hepatocyte pucks
and fibroblasts are encapsulated using a microfluidic droplet generating device to polymerize
-100 pm -diameter spherical cell-laden hydrogels. B) Phase image and viability staining of an
individual microtissue containing several hepatocyte clusters. The dotted line indicates the edge
of the hydrogel. Scale bar = 50 pm. C) Secreted albumin quantified from microtissues containing
either hepatocyte pucks only, hepatocyte pucks with a single-cell suspension of fibroblasts, or
hepatocyte-fibroblast mixed pucks. Error bars show standard error (SEM). n = 4 wells, * p =
0.0571, ** p = 0.0286, Wilcoxon rank sum test for pairwise comparisons.
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displayed the most optimal hepatic function as measured by total amounts of secreted albumin,
producing 70% more than microtissues containing hepatocyte pucks and fibroblasts mixed 24-
hours post-isolation (Fig. 4.6c).
Figure 4.7. Flow-focusing nozzle of microfluidic encapsulation device. Cell-containing
prepolymer reaches the junction from the left and is broken into droplets by perpendicular oil
streams coming from the top and bottom. 100 1 im-diameter droplets suspended in oil leave the
junction towards the right and are exposed to UV light immediately downstream.
Hepatocytes (Calcein) J2-3T3 (mCherry)
Figure 4.8. Sequential seeding of hepatocytes and fibroblasts to form mixed pucks. A)-C)
Fluorescent images of the two cell types right after seeding indicate distribution of fibroblasts
into each island. D-F) Cohesive mixed pucks after 24 hours of spreading with both cell types
incorporated. All scale bars = 200 pm.
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4.3.5 Species-specific cytochrome P450 enzyme activity
We further characterized the liver-specific functions of hepatic microtissues by assessing
their cytochrome P450 (Cyp) enzyme activity in response to known pharmacological inducers.
Microtissues were dosed with inducers omeprazole (50 .M), dexamethasone (10 1IM), rifampin
(25 1 M), or phenobarbital (200 jM) two days after encapsulation. After a 72 hours incubation
period, the activity of several Cyp isozymes was quantified and indicated levels of induction
that correlated well with the literature: 1 7, 18, 267, 268 a 9-fold increase in CyplAl activity by
omeprazole, a 7-fold increase in Cyp3A4 activity by dexamethasone, a 2-fold increase in
Cyp2C9 activity by rifampin, and a 2-fold increase in Cyp3A4 activity by phenobarbital (Fig.
4.9).
A CyplAl, 1B1 Activity B Cyp3A4 Activity C Cyp2C9 Activity D Cyp3A4 Activity(Luciferin-CEE) (Luciferin-PFBE) (Luciferin-H) (Luciferin-PFBE)
.- Z
CD CC
OpM 50pM' OpM 10pM 0 pM 25 pM 0 pM 200 pN
Omeprazole Dexamethasone Rifampin Phenobarbital
Figure 4.9. Induction of cytochrome P450 activity in hepatocyte-fibroblast mixed-puck
microtissues. A) CyplAl activity induced by 50 jM omeprazole. B) Cyp3A4 activity induced
by 10 jM dexamethasone. C) Cyp2C9 activity induced by 25 jM rifampin. D) Cyp3A4 activity
induced by 200 jM phenobarbital. Luminescent signals were scaled relative to uninduced
vehicle controls, all groups were n = 3. Error bars show standard error (SEM).
4.3.6 Acetaminophen toxicity
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To test the suitability of microtissues for 3D drug toxicity studies, we treated
microtissues with varying concentrations of the common analgesic, acetaminophen (APAP).
Acetaminophen is hepatotoxic only when metabolized by P450 enzymes, including Cyp3A4,
Cyp2E1, and Cyp1A2, 26 9 into the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI).
After treating microtissues with acetaminophen for 24 hours, we co-stained microtissues using
calcein AM (live) and ethidium homodimer (dead). The miniaturized 3D format of the
microtissues allowed us to use a large-particle flow cytometer for high-throughput detection of
individual microtissue viability in each treatment group (Fig. 4.10a). At lower concentrations of
acetaminophen (0 - 15 mM), the microtissue population was detected with generally high green
(live) fluorescence and low red (dead) fluorescence, and cluster in a line when represented on a
scatter plot (Fig. 4.10b). However, after treatment of microtissues with 40 mM APAP, a
population shift downwards (less green) and to the right (more red) indicates a range of
reduced viabilities within the microtissue population. By gating the microtissues to separate
those with typical post-encapsulation viabilities from those with exhibiting some level of
reduced viability, we were able to quantify the number of microtissues that fall above this
threshold as "% viable microtissues" (# of microtissue below gate / total microtissues in
population) (Fig. 4.10c). Microtissues that fall below this gating threshold indicate some level of
decreased viability i.e. more dead cells to live cells. Using % viable microtissues as a metric, the
dose curve of acetaminophen concentration displays a non-linear toxicity "shoulder" below
which there was little effect, but above which hepatotoxicity is observed, as has been reported5 9-
270 and is presumably due to depletion of intracellular glutathione.11, 27 1
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Figure 4.10. Acetaminophen-induced microtissue hepatotoxicity. A) Live-dead staining and
large particle flow cytometry to detect level of toxicity on a per-microtissue basis. B) Scatter
plots of microtissue fluorescence (green - live, red - dead) after 24 h incubation with various
doses of acetaminophen. Upper left gate indicates % of all microtissues in the population that
do not show reduced cell viabilities (% viable microtissues). C) Cliff-point for APAP toxicity
observed in % viable microtissue dose curve.
4.3.7 Cytochrome P450-mediated drug-drug interactions
We sought to explore a canonical example of drug-drug interactions, in which induction
of a Cyp enzyme by one drug may result in faster metabolism of a subsequent drug, affecting its
toxicity or efficacy. Since hepatic microtissues were previously responsive to Cyp induction, we
simulated co-treatment of the microtissues with 1) a pharmacologic inducer (omeprazole,
dexamethasone, rifampin, or phenobarbital), and 2) acetaminophen. Pre-incubation of
microtissues with omeprazole, which is reported to induce CyplA2,19 prior to treatment with
acetaminophen increased the amount of dead staining and increased the amount of live staining
compared to acetaminophen-only treated microtissues (Fig. 4.11a) as analyzed by large-particle
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with A) 50 1 M omeprazole, B) 10 1 M dexamethasone, C) 25 paM rifampin, or D) 200 FM
phenobarbital. Green - calcein, live. Red - ethidium homodimer, dead. B-H) Histogram
representation of microtissue populations, quantifying ratio of green vs. red signal with higher
ratios indicating a higher percent of viable cells in the microtissues. Treatment and control
groups were green: APAP only, red: inducer + APAP, blue: inducer only, black: vehicle control.
n > 1000, *** indicates p-value <10-4 (One-way ANOVA, Tukey post-hoc test).
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flow cytometry. Pre-treatment with dexamethasone, which is known to induce Cyp3A4
activity 17 (Fig. 4.9b) also exacerbated acetaminophen-induced hepatotoxicity (Fig. 4.11b).
Conversely, rifampin and phenobarbital, which are poor inducers of rat Cyp3A4 17, did not
significantly increase acetaminophen toxicity (Fig. 4.11c,d). Together, these data indicate that
hepatic microtissues are responsive to cytochrome-P450 mediated drug interactions.
4.4 Discussion
It has become increasingly clear that while hepatocellular carcinoma-derived cell lines
grow readily in culture, they are inadequate in vitro models for liver drug metabolism due to
low cytochrome P450 enzyme activity 2 , unresponsiveness to induction 31 , and reduced
sensitivity to hepatotoxins. 32 Primary hepatocytes remain the preferred cell-based model, but
are difficult to culture ex vivo, undergoing a rapid loss of liver-specific function and viability
when conventionally plated.59 Efforts to maintain freshly isolated hepatocytes have attempted
to replace some of the architectural and microenvironmental stimuli surrounding hepatocytes in
vivo, such as neighboring cells, extracellular matrix, soluble factors, and physical forces. 24,33 For
example, both homotypic and heterotypic cell-cell interactions have been reported to modulate
the function of primary hepatocytes in patterned 2D culture56 , 59 146 as well as in various 3D
culture systems.5 8, 62, 75, 114, 272
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Based on these reports, we hypothesized that facilitating physical cell-cell contacts
would be critical towards the function of primary hepatocyte-derived microtissues. Thus, we
chose to pre-aggregate hepatocytes into multicellular units before 3D encapsulation of the cells.
Furthermore, we sought to do so in a manner that could form uniform units (<100 tm) for
downstream microfluidic processing (i.e. for consistent flow), and was easily scalable to
millions of aggregates. Conventional techniques to form 3D aggregates, such as culturing cells
in rotational suspension,263 ,273 or on non-adhesive plates, 274 can take multiple days to incorporate
all cells, and lead to spheroids that are non-uniform in shape and size.69 , 263 To address this
problem, various techniques to enhance spheroid uniformity have been developed such as
hanging-drop platforms 27 or centrifugation into pyramidal microwells, 276 but are limiting in
both expense and throughput.
In this study, we have described a novel "2D to 3D" fabrication method to produce such
aggregates by seeding cells on large arrays of <100 tm micropatterned collagen islands, and
detaching intact cell-clusters from each island with collagenase (Fig. 4.1). The ability to define
different island sizes, and hence the number of cells per aggregate and the size of the detached
pucks, illustrates the control that can be achieved over puck characteristics and uniformity. As
an alternative to other 3D aggregation methods, our method additionally selects only for
adhesive hepatocytes in the freshly isolated population, filtering out any non-viable cells. Most
importantly, our method is orders of magnitude higher in throughput compared to hanging
drop (96 or 384 spheroids/plate) or microwell plates (28000 spheroids/plate), especially for small
aggregates. Using our method, one 6-well plate patterned with 50 Im islands can template over
600,000 pucks, or approximately 3x10 6hepatocytes assuming 5 hepatocytes per puck.
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To test our original hypothesis that pre-stabilized cell-cell contacts improve hepatocyte
function in 3D, we formed 50 pm pucks from primary rat hepatocytes and encapsulated them
within macroscopic PEG hydrogels. Using albumin production as a first-pass marker for
hepatocyte function, we found that pre-aggregation of the hepatocytes did indeed increase the
levels of albumin secreted from cell-laden hydrogels (Fig. 4.5c), which is consistent with
literature reports on the effects of homotypic hepatocyte interactions.46 ,si,277 The addition of co-
encapsulated J2-3T3 fibroblasts into the hydrogels improved hepatocyte performance even
more, corroborating the phenotypic advantage gained from co-culture,6 'ss-60,62-65,67 and extended
the albumin secretion capabilities of the hepatocytes to over 7 weeks (Fig. 4.5f). Interestingly,
further functionalizing the PEG hydrogel with adhesive RGDS peptides did not have a
significant effect on albumin production by encapsulated hepatocytes. Integrin ligation by
RGDS has been reported to confer survival to isolated hepatocytes through the Akt pathway 278.
Also, although cellular response to RGD can depend on how the peptide is presented (e.g.
clustering density"), we have conjugated RGDS to 10% PEG-DA hepatocyte-laden hydrogels
using the same co-polymerization route in the past.75 That RGDS was not a necessary for
optimal hepatocyte function is the present case may be due to cross-talk between cell-matrix
and cell-cell interaction pathways,91 , 92,241 and suggests that cell-cell contacts were sufficient to
alleviate the need for any cell-matrix contacts since the PEG hydrogel background is
biologically inert. An alternative explanation could be that collagenase detachment of the
hepatocyte pucks was sufficiently gentle on any extracellular matrix molecules (ECM) secreted
by and attached to the hepatocyte islands, such that the ECM was immobilized with the cells
during encapsulation and provided the appropriate matrix attachment cues.2 79
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Microfluidic encapsulation of hepatocytes raises several additional factors that must be
considered. Foremost among these is that although both microtissues and bulk gels are
photopolymerized from the same prepolymer composition, the continuous fabrication of
microtissues and therefore the short exposure time of prepolymer droplets in the device
necessitate much higher light intensities (500 mW/cm 2 instead of 21 mW/cm 2 ). Given the
theoretical mechanism of photoinitiation and free-radical polymerization, the small length scale
of the microtissues requires a higher concentration of radicals during polymerization to
overcome diffusion rates of radical-quenching oxygen into the droplet.2 16 Furthermore, primary
hepatocytes are known to be potentially sensitive to shear stress.33 ,280 , 28 1 Thus, while hepatocytes
have been reported to function in macroscale 3D scaffolds, 75,113,114 it is non-trivial to implement
a continuous, high-throughput fabrication process to miniaturize the gels. Despite these
challenges, we have verified by live-dead staining (Fig. 4.6b) and albumin (Fig. 4.6b) that
hepatocytes indeed remain functional as hepatic microtissues. We also determined that the
addition of fibroblasts by co-seeding fibroblasts onto hepatocyte islands most effectively
supports hepatocyte albumin production in microtissues compared to co-encapsulating
fibroblasts 24 hours post-hepatocyte isolation. This finding is consistent with the rapid decline
of hepatocytes without fibroblasts in 2D culture, where early physical contact, as opposed to
only soluble signaling, was critical in the first 18 hours post-isolation.146 By patterning co-
cultured pucks, we introduce supportive fibroblasts both earlier and in a closer configuration
(contact vs. paracrine), and further ensure that the two cell types do not separate during
microfluidic injection from size and density differences.
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Of the 500+ metabolic functions that hepatocytes perform in the body, xenobiotic
detoxification is essential in an in vitro model for drug development. We have shown activity in
the optimized hepatic microtissues of several major isozymes: Cyp1A1, Cyp3A4, and Cyp2C9
(Fig. 4.9). Moreover, we have demonstrated induction in metabolic activity in response to
omeprazole, dexamethasone, rifampin, and phenobarbital. Given these intact drug metabolism
characteristics, the miniaturized 3D format of microtissue culture enables high-throughput
toxicity and drug-drug interaction screens. Advantages of the microtissue system for such
purposes include being amenable to fast flow cytometry-like fluorimetric readout that provides
populational data. Experiments can be designed with large numbers of replicate gels for
statistical power but using reduced amounts of compounds, which may be limiting especially
earlier in the development process. For spheroid cultures, uncontrolled aggregation often
results in large spheroids with necrotic cores; 2 9, 260, 263, 280, 282 hepatic microtissues are protected
from both shear and aggregation, and can be cultured in small volumes without such
consequences.
As a proof of concept, we have illustrated a toxicity dose experiment with the hepatoxic
drug acetaminophen (Fig. 4.10). Overall levels of live (green) and dead (red) staining were
measured for each microtissue in control or APAP-exposed populations. Compared to pooled
biochemical assays such as MTT assays on 2D hepatocytes 9, this data provides information on
not only the average amount of hepatotoxicity observed but also the spread of responses from
the microtissue population (Fig. 4.10b). We have also executed a 6-day drug-drug interaction
experiment, in which we observed that omeprazole or dexamethasone pre-treatment
exacerbated acetaminophen toxicity (Fig. 4.11). Combined, these results suggest the utility of
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this system for screening new drug candidates, with the potential for longer treatment times
and complex dosing schemes (multiple doses, drug co-treatment) that cannot be performed in
short-lived liver slices or microsomes.
Throughout this study, primary rat hepatocytes were used to establish patterning and
encapsulation techniques. It is notable that the resulting hepatic microtissues effectively reflect
their species-specific origin. In our microtissues, we measured a 7-fold induction of Cyp3A4 by
dexamethasone, which is comparable to the fold inductions reported for rat hepatocytes (-3-8
fold from various donors while no induction was observed for human hepatocytes 17).
Accordingly, dexamethasone induction increased hepatotoxicity from acetaminophen exposure
(Fig. 4.11b), which is known to be metabolized through Cyp3A4. Phenobarbital and rifampin on
the other hand are strong Cyp3A4 inducers for human hepatocytes but less so for rat
hepatocytes1 8 , with phenobarbital causing only a 2-fold induction of Cyp3A4 in microtissues
(Fig. 4.9d). Thus as expected, phenobarbital and rifampin did not significantly affect
acetaminophen hepatotoxicity (Fig. 4.11c,d). Therefore, although the hepatic microtissues
characterized here may not be directly predictive of human clinical outcomes, these results
suggest that microtissues derived from human hepatocytes could potentially display human-
specific induction patterns.
4.5 Conclusion
In this study we utilized an array of microfabrication and microfluidic techniques to
encapsulate, for the first time, primary hepatocytes within PEG microtissues for stabilized long-
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term function. We have described a novel 2D to 3D method to facilitate the formation of cell-cell
contacts in a controlled and scalable manner. We have examined the influence of these
homotypic interactions as well as other factors on the survival and function of primary
hepatocytes when encapsulated in a 3D PEG scaffold, observing that hepatocyte-hepatocyte
contacts seem to alleviate the need for scaffold adhesion. After establishing an optimal
microtissue composition comprising mixed hepatocyte-fibroblast pucks, we have demonstrated
that these primary hepatic microtissues maintain their phenotype and display species-specific
responses to known inducers, and allow for a high-throughput detection of acetaminophen-
induced hepatotoxicity and CYP450-mediated drug interactions. Collectively, these techniques
present a versatile platform to model drug metabolism and toxicity. Future work will
incorporate automated liquid handling and more specialized fluorescent indicators of
hepatocyte injury.28 3
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Chapter 5: Modular Construction of a Primary Human Liver-on-a-Chip
5.1 Introduction
Nearly half a billion dollars of development cost is lost every time a drug fails in late-
phase development or is withdrawn from the market.1 The most common cause for such drug
candidate failure is unexpected liver toxicity," often arising from reactive metabolites33 that
were not observed in pre-clinical animal models and highlighting the need to assess human
responses to drugs. In vitro models based on human hepatocytes have the potential to model
human in vivo ADME/TOX (absorption, distribution, metabolism, and excretion/toxicity) more
quickly and accurately, reducing the need for and costs of animal testing. However, human
hepatocytes are notoriously difficult to culture ex vivo and rapidly lose their liver-specific
phenotype under conventional culture conditions.2 7 ,33 This has led to a variety of efforts to
optimize the culture conditions of human hepatocytes such as by providing media
supplements24,284, extracellular matrix, or co-culture with non-hepatic cell types2433. In this body
of work, it has been found that three-dimensional culture configurations, which better reflect
the natural architecture of the liver in vivo, improve maintenance of hepatocyte function
compared to that in 2D culture. 4 ,75,255,274,285-288 The perfusion of hepatocyte cultures, which
allows constant waste removal and stricter control of the culture microenvironment, has also
been reported to further improve many hepatocyte functions including albumin, urea, and drug
metabolizing activity compared to static cultures. 3 ,2, 289-295
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Microfluidic perfusion systems have been developed that benefit from the general
advantages of perfusion,296 ,297 but have been scaled down for drug development, requiring only
small volumes of reagents and offering the potential for integration with downstream organs to
study organ-organ interactions and integrated pharmacokinetic/pharmacodynamics modeling
(PK-PD)29 8,299. As perfusion of hepatocytes in 2D monolayers 29 7, 300 ,30 1 can incur shear stress-
induced damage 30 2 and display architecture-dependent phenotypic differences, 289 most efforts
have cultured cells in 3D formats, 298, 299, 301, 303-307 though many use hepatocarcinoma-derived cell
lines 298,299, 303 that inadequately represent primary hepatocyte drug metabolism. 2 ,29-32 Recently,
several groups have reported devices containing primary hepatocytes trapped between
microfabricated baffles simulating the hepatocyte-endothelial sinusoid barrier.3 0430 7 While
promising, this approach puts strict constraints on the specified device architecture, and is
difficult to extend to multi-organ systems. Additionally, microfluidic liver models in general are
frequently complex to use and limited by technical difficulties in cell loading.
Here, we report the microencapsulation of human hepatocytes with J2-3T3 fibroblasts in
poly(ethylene glycol) hydrogel to form 3D "microtissue" units (-100 pm diameter). These pre-
stabilized hepatic microtissues are modular1 48 199 and can be easily seeded into various perfusion
configurations, allowing versatile forms of co-culture with other cell types on-chip, or "un-
loading" and sampling of the microtissues for analysis. If desired, these modular liver units can
also be independently cultured and treated off-chip before loading into devices. To evaluate the
liver-specific activity of our microtissues, we characterize albumin production, Phase I drug
metabolism enzyme activity, and response to known hepatotoxins. By choosing to use primary
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hepatocytes as the cells in our model, we are able to detect human-specific enzyme induction
profiles, as well as donor-specific differences in metabolism. Finally, we demonstrate
microfluidic perfusion culture of the microtissues in a device consisting of an array of
microtissue traps, with intact drug metabolism, enzyme induction, and hepatocyte viability
persisting for over 3 weeks.
5.2 Materials and Methods
Cell culture
Cryopreserved human hepatocytes were purchased from Invitrogen. Donor lot Hu1434
was used for all experiments unless otherwise specified (see Table 1). Hepatocyte medium
consisted of high-glucose Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) with 10%
v/v fetal bovine serum (Invitrogen), 1% v/v ITS Premix (insulin, human transferrin, and
selenous acid, BD Biosciences), 0.49 pg/ml glucagon, 0.08 ng/ml dexamethasone, 0.018 M
HEPES, 10 U/ml penicillin, and 10 mg/ml streptomycin.
J2-3T3 fibroblasts (used at passage < 18) were a gift of Dr. Howard Green (Harvard) and
were cultured in DMEM with10% bovine serum (Invitrogen), 10 U/ml penicillin, and 10 mg/ml
streptomycin. Huh7.5 cells were generously provided by Dr. Charles Rice (Rockefeller) and
were cultured in DMEM with 10% fetal bovine serum (Invitrogen), 10 U/ml penicillin, and 10
mg/ml streptomycin. All cells were cultured in a 5% CO2 humidified incubator at 37'C.
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Table 5.1. Donors of cryopreserved human hepatocytes.
Spheroid formation
Plates for spheroid formation 2 7 6 containing continuous arrays of 100 Pm side-length
pyramidal microwells in 6-well plates were provided by Dr. Peter Zandstra (Toronto). Before
use, microwell surfaces were sterilized under UV for 15 minutes, passivated by soaking in 5%
w/v Pluronic F-127 (Sigma) in water for 1 hour at room temperature, and rinsed at least three
times in DMEM.
Freshly thawed human hepatocytes were resuspended with detached J2-3T3 fibroblasts
(0.25% trypsin-EDTA, Invitrogen) at a cell density of 500,000 cells/ml for each cell type (total
1x10 6 cells/ml). This mixed cell suspension was then transferred to the pyramical microwell
plates (12 ml per 6-well plate) such that theoretical average of 5 hepatocytes and 5 fibroblasts
would settle into each microwell. After allowing 15 minutes for cell settling, plates were
carefully moved to the incubator for spheroid formation overnight (18-24 hours).
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Donor Age Ethnicity Gender
Hu1420 68 Caucasian Female
Hul434 55 Caucasian Male
Hu4175 3 Caucasian Male
Hu4197 31 Caucasian Female
Hu4248 12 Caucasian Female
Hu8l32 57 Caucasian Female
Hepatocyte encapsulation in PEG gels
Spheroids were dislodged from microwells after overnight culture by gentle pipetting
and pelleted at 50xg, 5 min. Hepatocyte-fibroblast spheroids were then resuspended at an
effective cell density, calculated from initial cell numbers added to the microwells, of 8x10 6
hepatocytes/ml in PEG prepolymer. The prepolymer solution consisted of 100 mg/ml PEG-
diacrylate (20 kDa, Laysan Bio) in heavy DMEM (DMEM adjusted to have a specific gravity of
1.06 by OptiPrep density medium, Sigma) with 1:100 v/v% photoinitiator working solution (100
mg/ml Irgacure 2959, Ciba, in n-vinyl pyrrolidone, Sigma). Disc-shaped PEG gels were
fabricated using hydrogel polymerization apparatus."' Prepolymer solution containing cells
was loaded into a 8.5 mm diameter, 250 pm thick silicone spacer, sandwiched between a Teflon
base and a glass cover slip, and gelled by exposure to UV light from a spot curing system with a
collimating lens (320-390 nm, 21 mW/cm2, 12 s; Lumen Dynamics). Each gel was soaked in rinse
media for 1 hour to remove any un-polymerized components, and was subsequently cultured in
0.5 ml of hepatocyte medium. All experiments were performed with quadruplicate gels for each
condition.
Microfluidic hepatocyte encapsulation
Huh7.5 microtissues for validation of device design and basic parameters were
encapsulated as previously described. 264 For hepatocyte microtissues, spheroids were dislodged
from microwells after overnight culture and resuspended in prepolymer solution at a much
higher cell density than for disc-shaped PEG gels: assuming spheroids are half hepatocytes and
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half fibroblasts, the spheroids were resuspended to 1x10 6 hepatocytes/26.7 l PEG prepolymer.
Because of the high cell density, the PEG prepolymer for microfluidic encapsulation was
adjusted to account for the volume of the cell pellet: the initial prepolymer before adding cells
contained only 80% of the appropriate volume of DMEM, but the correct amounts of PEG and
initiator, so that the final concentrations with the volume of the cell pellet would be as described
above (100 mg/ml PEG-diacrylate, etc.).
The cell-prepolymer mixture was injected into a microfluidic encapsulation device as
previously described 308, where the spheroids are encapsulated into droplets of prepolymer in oil
and polymerized into microtissues. In a typical encapsulation procedure, spheroids would be
encapsulated in batches of 3x10 6 hepatocytes to reduce the amount of time hepatocytes were out
of the incubator and in microfluidic tubing. To minimize the number of empy, cell-free gels that
were formed, the flow of spheroids into the device was monitored by microscope and the
shutter on the UV lamp was temporarily closed whenever there was a period of low spheroid
density.
Microtissues collected from the device were separated from the heavier fluorocarbon oil
phase, filtered through a 132 pm nylon mesh to exclude large aggregates or debris, and then
washed on a 70 pm nylon mesh (Falcon) to remove any un-gelled cells and unreacted
components. For non-perfused culture, at this point microtissues were dispensed and
concentrated into 40 pm FACS tube cap strainers (BD Falcon) and cultured in Ultra-low
attachment plates (Corning) 24-well plates (650 l hepatocyte medium/well, changed every 2
days).
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Cytochrome-P450 studies
All chemicals were purchased from Sigma and stock solutions were prepared in DMSO
at 1000x final concentrations unless otherwise noted. For induction studies, microtissues were
cultured in strainers for at least 2-days post-encapsulation and then treated for 72 hours with
Cyp450 inducers 25-50 tm rifampin, 50 iam omeprazole, 10 tm dexamethasone, or 200-1000 LM
phenobarbital (stock solution 40 mM in water). For inhibition studies, Cyp450 inhibitors
8'methoxypsoralen (25 KM), sulfaphenazole (50 raM), quinidine (10 raM), or thioTEPA (10 pM)
were added to microtissues for 1 hour prior to and during incubation with Cyp450 substrates:
coumarin (50 pM), ethoxyresorufin (5 pM), bupropion (100 pM), S-mephenytoin (100 pM),
dextromethorphan (100 pM), or testosterone (100 1aM) for 3 hours at 37'C.
Glucoronidase/sulfatase-mediated phase II metabolites from coumarin or ethoxyresorufin were
hydrolyzed by incubating with p-glucuronidase/arylsulfatase (Roche) for 2 hours at 37 'C. The
metabolites of coumarin and ethoxyresorufin were quantified at wavelengths of 355/460 ex/em
and 560/610 ex/em respectively. Metabolites of bupropion, S-mephenytoin, dextromethorphan,
and testosterone were quantified by HPLC (Integrated Analytical Solutions). Cyp450 activity
was also quantified using P450-Glo assay kits (Promega): microtissues were incubated with
substrates luciferin-IPA (1:1000 dilution, Promega), luciferin-H (1:50, Promega), or luciferin-
CEE (1:50, Promega) for 3 hours at 37 'C. Corresponding metabolites were detected in the
microtissue supernatant using a luciferin detection reagent and a luminometer (10 s integration
time, Berthold) according to assay instructions.
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Device fabrication and loading
Standard photolithographic methods (SU-8 2050 photoresist, 125 jim thickness) were
used to fabricate silicon masters for encapsulation devices and perfusion chamber devices.
Sylgard 184 elastomer (PDMS, Dow Corning) devices were cast from the masters and
inlet/outlet holes were punched using a 20G dispensing needle (McMaster Carr). Devices were
bonded to glass slides after air plasma treatment (5 second) and baked on a 125'C hot plate for 5
minutes to strengthen the bond. Finally, the inner channels of encapsulation devices were
coated with a hydrophobic silane (Aquapel). Perfusion devices were sterilized with 70% ethanol
just before use, which also served to wet the inner surfaces of the chamber and prevent bubble
formation, and was then flushed out of the device with medium. Tubing and connectors were
sterilized by autoclave.
Perfusion devices were loaded on the day of microtissue encapsulation, though
microtissues could also be cultured off-chip before loading. Newly washed microtissues were
transferred off of 70 jim strainers in hepatocyte medium and injected by hand (flow rates -20
I/second) into the inlet of each perfusion device. Loading progress of each device was checked
under the microscope to verify that all traps were filled. Microtissues that passed through the
device without being captured were re-collected at the outlet and re-injected if necessary.
Device operation
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Loaded liver-chip devices were cultured in a 5% CO2 humidified incubator at 370C. A
multi-channeled external pump was connected to the outlet of each device in order to pull
media through the device from an inlet reservoir (Fig. 5.1).
A
Inlet reservoir
U-
Perfusion chamber Syringe pump
B
Perfusion chamber Peristaltic pump Outlet reservoir
Figure 5.1. Setup and operation of microtissue perfusion chamber. (A) After loading
microtissues via the inlet (left side) of each device, devices are connected by tubing to an inlet
medium reservoir. A syringe pump actuates flow of the medium through the perfusion
chamber (3-121 1d/hr), and spent medium is collected within the outlet tubing between the
device and the syringe. (B) For parallel perfusion of multiple devices, a peristaltic pump is used
to pull medium from the inlet reservoir through the device into the outlet (24 1tl/hr). During
metabolism assays, the inlet reservoir is replaced with a solution containing probe substrates,
and metabolites are collected in the outlet reservoir.
To perfuse devices with various flow rates simultaneously, a syringe pump (Harvard
Apparatus) was set up with syringes (BD, plastic) of several different inner diameters, such that
a given linear displacement by the pump would withdraw different volumes of perfusate.
Syringes were connected by extensive Tygon tubing to the outlet of each device, and were
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Inlet reservoir
initially filled with Fluorinert FC-40 (Sigma). During operation, spent medium that has passed
through the device was collected in the long outlet tubing, which was disconnected daily and
dispensed into collection tubes. Collected samples were then diluted to an equal final volume in
fresh medium.
No-flow control devices that were loaded with microtissues but not perfused contained
only the initial 15 1ti of hepatocyte medium from the loading process. To prevent evaporation,
devices were placed in a dish and submerged in just enough medium to cover the top of the
PDMS device. The inlet and outlet holes of the PDMS device were small and, being in silicone,
often self-seal when tubing is not connected. Preliminary experiments using food coloring
indicated no visible transfer of liquid between inside the device and the submerging medium.
Spent media samples from no-flow devices were collected by washing out the retained liquid
with a known amount of fresh medium, and then further dilution to the same final volume of
perfused media samples.
Simultaneous operation of larger numbers of devices in parallel (up to 24) was
performed on a peristaltic pump (Ismatec). Medium was pulled from a reservoir through the
devices at 24 l/hr and directly into collection tubes that were collected daily. To perform
biochemical assays on devices, the inlet of the device was moved to pull from another reservoir
containing assay reagents rather than medium.
Albumin quantification
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To track albumin production from hepatocytes, supernatant was collected every other
day from bulk gels or microtissues in strainer, and output perfusate from devices was collected
every day. The albumin concentration in each sample was quantified by an enzyme-linked
immunosorbent assay (ELISA) using sheep anti-rat albumin antibodies (Bethyl Labs) and
horseradish peroxidase detection (3,3',5,5'-tetramethylbenzidine, Invitrogen).
Toxicity experiments
For hepatotoxicity experiments, microtissues were cultured for 72 hours post-
encapsulation and then exposed to 0-70 mM acetaminophen, 0-60 mM cyclophosphamide, 0-500
4M troglitazone, 0-350 tM chlorpromazine, or 0-120 4M imipramine for 24 hours (all chemicals
purchased from Sigma). Final DMSO was kept under 0.8% v/v in hepatocyte medium. For drug
interaction experiments, microtissues were cultured for 48 hours post-encapsulation, exposed to
either 2 mM n-acetyl cysteine (NAC) or 1 mM buthionine sulfoximine (BSO) for 24 hours, and
then dosed with 40 mM of acetaminophen with continued presence of NAC or BSO for 24
hours.
Large-particle flow cytometry
High throughput analysis of microtissue viability was performed by first staining
microtissues in suspension with the live-dead fluorescent stains calcein AM (5 Pg/ml) and
ethidium homodimer (2.5 .g/ml) for 15 minutes at 370C. Whole-microtissue levels of
fluorescence were detected using a BioSort large particle flow cytometry (Union Biometrica)
equipped with a 488 nm excitation laser. Microtissues were gated for on the basis of Time of
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Flight (size) and Extinction (optical density) to exclude debris. Fluorescent signal acquisition
parameters were set as follows: Gains - Green 3, Red 3, PMT control - Green 300, Red 700.
Compensation was applied to subtract 90% of the green signal from red. Scatter plots were
created using BioSorter software. Raw data was also exported for processing with custom
MATLAB code.
5.3 Results and Discussion
5.3.1 Primary hepatocyte microtissue fabrication
We have previously reported the fabrication and optimization of hydrogel-encapsulated
microtissues using primary rat hepatocytes.3 08 In that work, we found that establishing cell-cell
contacts by pre-aggregating hepatocytes with J2-3T3 fibroblasts before encapsulating was
essential towards improving the function of resulting 3D tissues. Extending this principle to
human hepatocytes, cryopreserved hepatocytes were thawed and seeded with a 1:1 ratio of
fibroblast into 100 tm side length pyramidal PDMS microwells (Fig. 5.2). Over 24 hours, cells in
each microwell (on average 5 hepatocytes and 5 fibroblasts) formed spheroids that were
approximately 50 Vm-diameter. In the absence of fibroblasts, hepatocytes-only aggregates did
not form compact spheroids within 24 hours (data not shown). For such small spheroids and
short times, the 100 pm side length microwells are ideal and increase throughput 16x compared
to the commercially available 400 pm side length microwells. However, because the smaller
microwells are shallower, they cannot accommodate larger cell numbers per spheroid, and
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spheroids are more easily disrupted into nearby wells over multiple days of culture especially
during medium changes.
A B_ C
Figure 5.2. Mixed hepatocyte-fibroblast spheroid formation in pyramidal microwells. Freshly
thawed hepatocytes and singly-dissociated J2-3T3 fibroblasts were combined at a 1:1 ratio and
allowed to settle in pyramidal microwells such that on average, each microwell would contain 5
hepatocytes and 5 fibroblasts. (A-B) Phase contrast microscopy showing spheroid formation
after 24 hours. (C) Spheroidal aggregates removed from microwells for subsequent
encapsulation. All scale bars = 100 pm.
In our case, hepatocyte-fibroblast spheroids were removed from the microwells after one
day and encapsulated within photopolymerized 10% PEG-DA hydrogels using a microfluidic
droplet-generating device.30 Resulting mixed spheroid-laden microtissues secreted albumin for
over two weeks (Fig. 5.3a), whereas microtissues containing only hepatocyte aggregates were
only minimally functional for the first week, confirming the supportive nature of J2-3T3
fibroblasts on human hepatocyte function in the microtissue format. Because donor lots of
human hepatocytes can vary in both inherent biology and response to cryopreservation, we
repeated this co-culture and encapsulation process with multiple lots (Fig. 5.3b). We found that
in each case, hepatocyte function was successfully stabilized and albumin was secreted into the
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supernatant from PEG-DA gels for over two weeks, confirming that the pre-aggregation and
scaffold composition are robust for hepatocytes from a range of donor individuals.
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Figure 5.3. Albumin secretion by encapsulated primary human hepatocytes. (A) Supernatant
concentrations of albumin from 10% PEG-DA microtissues containing either hepatocyte-only
spheroidal aggregates, or hepatocyte-fibroblast spheroidal aggregates. (B) Supernatant
concentrations of albumin from 10% PEG-DA gels (8.5 mm-diameter x 0.25 mm thick) with
hepatocyte-fibroblast spheroidal aggregates from various hepatocyte donor lots.
5.3.2 Species- and donor-specific drug metabolizing enzyme activity
To assess the utility of hydrogel-encapsulated microtissues as an in vitro model of drug
metabolism, we characterized microtissue cytochrome P45 (CYP450) activity as a more stringent
measure of organ-specific activity beyond albumin production. Cytochrome P450s are a class of
Phase I enzymes that are responsible for approximately 75% of total drug metabolism.33 Many
drug interactions leading to changes in drug efficacy or safety are modulated through CYP450
induction or inhibition. Microtissues were first stimulated to upregulate enzyme production
using clinical inducers for 72 hours, and then exposed to fluorometric and luminescent
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substrates for specific CYP isozymes (Fig. 5.4). Induction profiles in the microtissues at Day 5
post-encapsulation correlated well with literature reports: pre-incubation with rifampin
induced Cyp3A4 (10-fold),17 ,309 Cyp2A6 (1.5-fold),310 and Cyp2C9 (3.5-fold).309 Phenobarbital
induced Cyp3A4 (5-fold) and Cyp2A6 (1.7-fold), 310 and omeprazole induced CyplAl (3-fold)
and CyplA2 (350-fold).19 The pattern of human CYP450 induction represented here is not
generally not observed in hepatocellular carcinoma cell lines, 31' 32 which renders the latter
insufficient for predicting CYP450 mediated drug interactions. Furthermore, several of the
induction interactions observed here are species-specific. For example, rifampin has been
reported to induce Cyp3A4 for human hepatocytes but not rat hepatocytes." Similarly, CyplA2
is induced by omeprazole in human hepatocytes but much less so in rat hepatocytes.19
Conversely, dexamethasone is a strong inducer of Cyp3A4 in rat hepatocytes but not in human
hepatocytes 17 (Fig. 5.4a). We also tested the inhibition of CYP450 enzymes using several known
inhibitors, and observed as expected reduced Cyp3A4 activity in the presence omeprazole (Fig
5.4a),31' 312 Cyp2A6 inhibition by 8-methoxypsoralen3 13 (Fig. 5.4b), and Cyp2C9 inhibition by
sulfaphenazole (Fig 5.4c). 314, 315 Taken together, this evidence supports the conclusion that
microtissues are effective at stabilizing the drug metabolism functions of primary human
hepatocytes, and highlights why in vitro human cultures can be more predictive of in vivo
human liver response than animal models.
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Figure 5.4. Induction of cytochrome P450 activity in primary human hepatocyte microtissues.
(A) Cyp3A4 activity as evaluated by luciferin-IPA metabolism in response to inducers (72
hours) rifampin, phenobarbital, or dexamethasone, and weak inhibitor omeprazole. (B) Cyp2A6
activity evaluated by coumarin metabolism to coumarin 7-hydroxylase in response to induction
by rifampin and phenobarbital, or inhibition by 8-methoxypsoralen. (C) Cyp2C9 activity
evaluated by luciferin-H metabolism as induced by rifampin or inhibited by sulfaphenazole. (D-
E) CyplAl and CyplA2 activity evaluated by luciferin-CEE and 7-ethoxyresorufin metabolism,
respectively, when induced by omeprazole.
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We also sought to examine whether microtisuses had the potential to accurately reflect
donor specific differences in drug metabolism. On Day 5 post-encapsulation, baseline, induced,
and inhibited Cyp3A4, Cyp2D6, Cyp2C19, and Cyp2B6 activities were quantified in
microtissues derived from two different donor lots, Hu1434 (Donor A) and Hu4175 (Donor B)
(Fig. 5.5). CYP2D6 and CYP2C19 are known to have genetic polymorphism, with resulting
inter-individual variability in drug clearance through these pathways. 13,3 16 In the Caucasian
population, to which both donor lots belong, approximately 10% of individuals are considered
low 2D6 metabolizers, 317 while approximately 5% are low 2C19 metabolizers 12 . Thus, it is
particularly notable that in our microtissue model, Donor A exhibits 3.4-fold higher baseline
Cyp2D6 activity than Donor B (Fig. 5.5c, d). Cyp2D6 activity metabolized about 25% of
clinically used medications 317 and is generally one of the most difficult hepatocyte functions to
maintain under non-optimal culture conditions;29 its presence here speaks to the functional
stability of hepatocytes in microtissue culture. The concentration of metabolites processed by
Cyp2D6 by Donor B is as low as the activity for either donor in the presence of the inhibitor
quinidine (Fig. 5.5c,d), suggesting that Donor B may have been an inherently low 2D6
metabolizer. Genotyping of the two donors could confirm this hypothesis. On the other hand,
Donor A had almost undetectable Cyp2C19 activity (Fig. 5.5e), whereas microtissues from
Donor B were 60-fold more active (Fig. 5.5f). Similar fold-inductions were observed after 2
weeks of microtissue culture (data not shown). The ability to model such a range of donor
characteristics will be crucial in screening drug candidates; for example, a given dose may not
affect the average population but could lead to a toxic buildup in low metabolizing individuals.
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Figure 5.5. Comparison of cytochrome P450 activity (Day 5) between donor individuals.
(A,C,E,G) HPL C quantification of metabolites produced by Hul434 microtissues. (B,D,F,G)
HPLC quantification of metabolites produced by Hu4175 microtissues. Arrows in (E) and (F)
indicate metabolite concentration below detectable limit. Inducers and inihibitors used were
rifampin (RIF), quinidine (QUI), omeprazole (OME), and thioTEPA.
5.3.3 Microtissue response to hepato toxic drugs and drug interactions
We next treated microtissues with several model hepatotoxins to validate the
responsiveness of microtissues to hepatotoxic insults (Fig. 5.6). One of these was acetaminophen
(APAP), which is itself nontoxic but is converted by CYP450 enzymes in the liver into the
reactive metabolite N-acetyl-p-benzoquinone (NAPQI)2 71. NAPQI can be inactivated by
intracellular glutathione, but accumulates to toxic concentrations when glutathione reserves are
depleted 2 1 . As a first pass, our readout for microtissue toxicity was a live/dead stain using
calcein AM (green, live) and ethidium homodimer (red, dead). Microtissues were incubated
with a range of acetaminophen concentrations for 24 hours, stained, and analyzed using a large
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Figure 5.6. Microtissue hepatotoxicity as measured by large particle flow cytometry. Data
points indicate shift in peak green/red (live vs. dead) peak location with increasing
concentrations of (A) chlorpromazine, (B) imipramine, (C) troglitazone, and (D)
cyclophosphamide.
particle flow cytometer. On scatter plots of microtissue fluorescence, dose-dependent
hepatotoxicity was observed, with the detected microtissue population shifting farther to the
right (more dead staining) and down (less live staining) with increasing concentrations of
acetaminophen (Fig. 5.7a).When the ratio of green signal vs. red signal is quantified for each
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Figure 5.7. Acetaminophen-induced hepatotoxicity in human hepatic microtissues. (A) Large-
particle flow cytomettry scatter plots of live/dead (green/red) stained microtissue populations
when exposed to increasing concentrations of acetaminophen for 24 hours. (B) Histogram
quantification of each microtissue population, measuring the ratio of green to red fluorescence
in each microtissue. (C) Plot of histogram peak locations. Initial data point at 0 mM APAP
indicates fully viable microtissues, whereas 60 and 70 mM data points indicate toxicity to all
cells within each microtissue.
population, as a measure of % cell viability in each microtissue, histograms curves (Fig. 5.7b)
also display decreasing log(green)/log(red) peak locations (Fig. 5.7c) with increasing
acetaminophen concentration. To further investigate whether the observed toxicity is consistent
with the proposed acetaminophen mechanism, we pretreated microtissues with either
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(Fig. 5.8).
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Figure 5.8. Mechanism-based drug interactions with acetaminophen toxicity. (A) Scatter plots
of live/dead (green/red) stained microtissues after exposure to acetaminophen or combinations
of acetaminophen with N-acetyl cysteine (NAC) or buthionine sulfoximine (BSO). (B)
Histogram quantification of treated microtissue populations.
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5.3.4 Design and operation of microfluidic perfusion chamber
To illustrate the application of hepatic microtissues in a perfused device, we designed a
simple microfluidic chamber containing an array of C-shaped microtissue traps (Fig. 5.9). The
inner diameter of the traps was selected to be 500 pm so that each trap holds approximately 10
microtissues. We chose to trap microtissues in groups of 10 to allow some local interaction
between the microtissues via secreted soluble factors, but balancing this against the diffusive
distance between the perfusate flow and the center of the microtissue clusters. The shape and
spacing of the traps in an array were then optimized for capture efficiency, defined as the
number of gels passing through the device that are retained in traps. We found that straight
outer edges and backs on each trap helped direct microtissues into the next row of traps:
microtissues would need to make nearly a 90' turn to escape (Fig. 5.9c). If the edges and
bottoms of the traps were semi-circular, laminar flow around the edges helped microtissues
establish a sine-like flow path and escape all subsequent traps. During microtissue loading into
our final devices (Fig. 5.9c), traps fill in rows from the first row (left) backwards, which signifies
that microtissues are escaping to subsequent traps only if there is no longer space in the prior
traps.
As the supply of human hepatocytes is limited, we first explored the operating
parameters of the device using microtissues containing Huh7.5 cells. Devices were loaded with
Huh7.5 microtissues and perfused with standard culture medium at various flow rates: 3 1i/hr,
19 !1l/hr, 62 pl/hr, and 121 1tl/hr. At all flow rates except the highest, microtissues remained
viable after 3 days as visualized by calcein staining, and Huh7.5 cells seemed to be proliferating
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Figure 5.9. Microtissue trapping and perfusion device. (A) Schematic of the device
illustrating fluid flow (red - high velocity, dark blue - low velocity) between semicircular traps.
(B) Photograph of device filled with colored solution. (C) Phase microscope image of
microtissues loaded into traps. (B-C) Scale bar = 500 im. (D-E) Phase and live/dead fluorescent
images of Huh7.5 microtissues in individual traps after 72 hours of perfusion (19 l/hr).
by morphology (Fig. 5.10d, e). While device oxygenation is considered to be a major role of
fluid perfusion,318 microtissues were viable even in un-perfused devices, showing that sufficient
amounts of oxygen are able to diffuse through the gas-permeable PDMS device3 19, and that the
small 15 1d volume of medium in the chamber provides sufficient nutrients for 24 hours. The
output medium from perfused and un-perfused devices was monitored for albumin secreted by
Huh7.5 cells (Fig. 5.10); the successful detection of albumin confirms the ability for small
molecules and proteins to transport between the convective flow areas of the device, and
microtissue-encapsulated cells in the traps. Optimal albumin production from devices was
observed between 19-62 1p/hr. A flow rate of 24 1l/hr (576 p1/day) was selected for further
experiments, and produces a estimated flow velocity of 25 pm/s that is comparable to other
perfused hepatocyte systems 30 . Flow rates higher than 121 p1/hr were visibly detrimental to
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Huh7.5 proliferation and morphology over several days. Accordingly, the albumin output from
devices at high flow rates was much lower than at lower flow rates (Figure 9). While high flow
rate can be detrimental to cell function due to shear-induced damage2 89 , cells within
microtissues should be protected from shear stress by the hydrogel coating 262 as well as flow
profiles around the traps. We have postulated that the higher flower rates are instead diluting
out secreted cell-cell interaction molecules.32 ' 32 1
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Figure 5.10. Albumin detected in perfusate of Huh7.5 microtissue-loaded devices. Albumin
concentrations were normalized to those from 19 1tl/hr devices.
Having established that the device architecture and operating procedures were
cytocompatible, we next loaded microtissues containing primary human hepatocytes into
chamber devices and perfused them with hepatocyte medium at a volumetric flow rate of 24
l/hr. The output media from each device was collected and analyzed for secreted albumin over
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time (Fig. 5.11a). Albumin production was in the range of 100-300 ng/day/device, corresponding
to about 10-20 pg/10 6 hepatocytes/day and persisting for over 21 days. This three-week
longevity will be important for the study of any effects that occur only after temporal sequences
of drug combinations, or chronic exposure to liver metabolites. In one such scenario, a pro-drug
may be converted in the liver compartment to a metabolite whose exposure slowly induces
toxicity on a downstream organ model over time. To demonstrate the metabolism of drug
passing through the microtissue liver device, we perfused devices with coumarin and detected
rates of metabolite formation comparable to that of microtissues off-chip (Fig. 5.11d).
Omeprazole induction of CYP1A1 substrate metabolism (Fig. 5.11b) and rifampin induction of
Cyp2C9 substrate metabolism (Fig 5.11c) were also intact and comparable to fold-inductions
off-chip (Fig 5.4c, d). Collectively, these findings signify that liver-specific functions are
maintained on this easily assembled device, and underscore the suitability of human hepatic
microtissues for organ-on-a-chip systems.
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Figure 5.11. Characterization of hepatocyte functions in microtissue perfusion device. (A)
Amount of albumin secreted by microtissues into perfusate over time. (B) Induction of Cyp2C9
activity (Day 14) by 72 hours of exposure to rifampin in the perfusate. (C) Induction of CyplAl
activity (Day 5) by 72 hours of exposure to omeprazole in the perfusate. (D) Rate of coumarin 7-
hydroxylation by microtissues cultured off-chip (static) compared to metabolism rate in one
pass through microtissues on-chip (perfused).
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5.4 Conclusion
We have developed a method to produce human hepatocyte-laden microtissues,
containing hepatocyte-fibroblast aggregates in a miniaturized hydrogel scaffold, for modular
seeding of in vitro liver-on-a-chip devices. The microtissues exhibited species-specific
cytochrome P450 induction and inhibition profiles in response to known drugs, as well as
reactive metabolite-induced hepatotoxicity, attesting to the stabilization of liver-specific
phenotype in the microtissues. We were also able to detect donor-specific differences in Cyp2D6
and Cyp2C19 activity, which would not have been possible using existing hepatic cell lines. For
further individualized models of drug metabolism, future efforts will focus on encapsulating
induced pluripotent stem cell-derived hepatocytes into microtissues. We have also designed
and tested a trap-based microfluidic compartment that efficiently captures and retains
microtissues for perfusion culture over 3 weeks, and permits interrogation with soluble drugs.
Future work will integrate microtissues into devices with more complex flow geometries, for
example those incorporating branching endothelial-lined channels or with built-in oxygenation
gradients. We envision that such liver-on-a-chip systems, especially in conjunction with multi-
organ models, have the potential to accelerate pre-clinical drug development and dramatically
reduce clinical trial attrition.
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Chapter 6: Perspectives and Future Direction
6.1 Microfluidic Fabrication of 3D Microtissues
In this thesis, we explored the construction of defined cellular microenvironments
through the paradigm of individually stabilized, 3D microtissue units. We first designed a
microfluidic device in Chapter 2 that uses flow-focusing to encapsulate cells into droplets of pre-
polymer in oil, which were photopolymerized on-chip to produce 100 pm-diameter spherical
PEG microtissues. Throughout Chapters 3-5, we encapsulated a range of mammalian cells
including primary liver, tumor, and stromal cells, validating the first continuous process to
quickly manufacture uniform microtissues while preserving the long-term (-weeks) survival,
function, and proliferation of encapsulated mammalian cells. Several groups in parallel have
since described similar microfluidic droplet-based encapsulation strategies using alginate, 4 1
agarose,139 or self-assembling peptide gels,322 though these alternative materials have inherent
cell-interactive properties and thus do not offer the combination of blank background and ease
of modification that PEG hydrogels do.
Although we have shown here that a single flow-focusing junction can generate 101
microtissues/hour, in the future we will be pursuing even higher production rates to facilitate
larger-scale drug screening or bottom-up microtissue assembly. New device designs with many
parallel microtissue encapsulation junctions are being tested. These will require uniform UV-
illumination over a wide area of polymerization channels, and must avoid the scattering of light
to other regions of the device3 23 to avoid premature polymerization. To address any concerns
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about the use of UV light, future prepolymers can incorporate novel photoinitiators that absorb
in the visible-light range.120
6.2 Systematic Control of Microenvironmental Stimuli
Leveraging various microfabrication and bioconjugation techniques, we have
demonstrated methods to control the interactions of cells in microtissues with other co-cultured
cells, extracellular matrix, and soluble stimuli. These platforms open the door to numerous
investigations surrounding the influence of specific microenvironmental stimuli on cell fate and
function, especially when such cues are interpreted by cells cultured in a 3D setting. For
example, ongoing studies are testing whether the co-encapsulation of particular stromal cell
lines can confer chemoresistance to tumor cells from a range of tissue origins, similar to screens
that have been previously performed on 2D cultures. 219 As seen in the different opposing
responses of mouse lung adenocarcinoma cells to TGF-p and to a TGFpR1/TGFpR2 inhibitor
(LY2157299) when cultured in a 2D plate compared to in 3D microtissues (Chapter 3), the
thorough study of tumor biology and response to therapy is be contingent on having an
appropriate in vitro model. Future work is required to confirm whether 3D tumor models are
indeed more predictive of human in vivo response to chemotherapeutics: a follow-up study to
our work here could be to compare results from individual patients in clinical trials of
LY2157299, with the effect of the drug on microtissues containing biopsied tumor cells.
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6.3 High-Throughput 3D Phenotypic Screening
Towards high-throughput microtissue-based drug screening, we have developed a
platform based on large populations (n > 1000) of 3D microtissues to measure cancer cell
proliferation in response to chemotherapeutic candidates, or liver tissue injury in the presence
of potential hepatotoxins. By using a flow cytometry-like readout for these screens, we were
able to quickly measure fluorescent labels of cell density or cell viability for each individual
microtissue in a treatment group, providing information on both population average and
spread.
In order to investigate hepatotoxicity using an ideally relevant model cell type, we
examined factors to maintain primary human hepatocyte function in microtissues for the first
time (Chapters 4-5), validated by the preservation of important drug metabolizing cytochrome
P450 enzymes and sensitivity to known hepatotoxins and drug combinations. It is particularly
interesting that depending on the donor lot of cryopreserved hepatocytes used, resulting
microtissues metabolized test substrates for CYP2D6 and CYP2C19 at different rates. Up to 10%
of Caucasians are poor CYP2D6 metabolizers and up to 5% are poor CYP2C19 metabolizers.13
That microtissues reflect individual liver phenotypes could be useful in pre-clinical studies to
detect idiosyncratic toxicity due to donor-specific enzyme polymorphisms, or to identify target
patient populations for clinical trials.316
In these studies we have performed toxicity assays on uniform hepatic microtissues, but
a future area of investigation could be to mix and match the types of microtissues cultured
together. Hepatic microtissues could be mixed in a single well with microtissues containing
cardiomyocytes, for example, to assess if liver metabolites of a drug candidate caused
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cardiotoxocity. Similarly, some pro-drugs might require activation by liver microtissues before
they are effective on nearby tumor microtissues. The modularity of microtissue culture allows
the two cell types to be co-cultured and exchange soluble signals, but then later be decoded 149
and analyzed separately to decouple any hepatotoxicity from potential anti-tumor activity.
Looking forward, while this thesis uses the live-dead stains calcein AM and ethidium
homodimer as a proof of concept for toxicity screening, a wide array of fluorescent stains or
genetic labeling is available to probe more subtle measures of hepatocyte damage, such as
mitochondrial abnormalities, lipid accumulation, oxidative stress, and intracellular glutathione
depletion.283
Successful long-term culture of human microtissues could also have important future
applications in vivo as injectable implants for disease therapy or to "humanize" mouse livers, 75
obviating the need for invasive surgical procedures. An optimized microtissue scaffold could
protect and provide stabilizing signals for hepatocytes, potentially improving engraftment
efficiencies in various locations. Further exploration of scaffold modifications, especially
towards cell-degradable PEG materials, 1211 25 , 31 , 324 will be of benefit for vascularization and
permanent integration of implanted microtissues.
6.4 Towards Modular Organ-on-a-Chip Devices
In Chapter 5, we encapsulated primary human hepatocytes in microtissues with the
ultimate objective of being able to modularly seed hepatocytes into a range of liver-on-a-chip
device designs. Using a proof-of-concept microfluidic chamber containing an array of
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microtissue-retaining traps, we demonstrated that at optimal flow rates (20-60 l/hr) hepatic
microtissues remained viable and continued to secrete albumin during over 3 weeks of
perfusion. We also detected drug metabolism of perfused substrates and induction by rifampin
and omeprazole on-chip. Together, these results verified transport of proteins and small
molecules to and from encapsulated cells via convective fluid transport and then diffusion
through the microtissue hydrogel scaffold, and suggest the utility of such devices as metabolite-
generating liver compartments for integration with multi-organ models. In order for on-chip
results to be clinically relevant, further experiments will be necessary to correlate rates of
metabolite production and area under the curve (AUC) data on-chip with clearance rates in
vivo.
Future directions will leverage microtissue modularity to populate increasingly complex
devices with these pre-stabilized hepatocyte units, for example to incorporate vascular-like
branching, endothelial lined channels, or chemical and oxygen gradients. Hepatocytes have
been shown to have CYP450 profiles that depending on position along an oxygen gradient,291
representing centrilobular vs. periportal phenotypes. 237, 23s Spatial differences in sensitivity to
systemic hepatotoxins can also arise due to higher concentrations of metabolites accumulating
downstream i.e. in the centrilobular zone.325 Perfusion systems that encompass such additional
facets of tissue physiology could further improve the modeling of the human body on-chip.
Finally, to address the lack of appropriate hepatic cell lines and when primary cells are not
practical options, induced pluripotent stem (iPS) cells may provide an alternative solution to
cell sourcing and produce individual-specific iPS-derived hepatocyte-like cells (iHLCs) with
unique genetic backgrounds.326 Future undertakings will endeavor to encapsulate and maintain
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iHLCs in microtissues while directing their differentiation past the current fetal hepatic
phenotype into mature hepatocytes.
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